Refine Search

Search Results -

Terms	Documents
tobramycin near5 prodrug	1

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L3

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Friday, November 30, 2007 **Purge Queries** Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L3	tobramycin near5 prodrug	1	L3
L2	L1	0	L2
DB=USPT; PLUR=YES; OP=OR			
L1	aminoglycoside near5 prodrug	0	L1

END OF SEARCH HISTORY

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:40:39 ON 30 NOV 2007

=> file ca

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CA' ENTERED AT 11:41:07 ON 30 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 29 Nov 2007 VOL 147 ISS 24
FILE LAST UPDATED: 29 Nov 2007 (20071129/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s aminoglycoside and prodrug
9516 AMINOGLYCOSIDE
11921 PRODRUG
L1 55 AMINOGLYCOSIDE AND PRODRUG

=> d l1 1-55

L1 ANSWER 1 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 147:462234 CA
TI Method using an antimicrobial compound for reducing the risk of or preventing infection due to surgical or invasive medical procedures
IN Hopkins, Scott J.; Kessler, Robert E.; Collinson, Albert R.; Sutcliffe, Joyce A.
PA USA
SO U.S. Pat. Appl. Publ., 35pp., Cont.-in-part of U.S. Ser. No. 706,932.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2007249577	A1	20071025	US 2007-784091	20070404
	US 2007238719	A1	20071011	US 2006-432228	20060510
	US 2007238720	A1	20071011	US 2007-706932	20070213
PRAI	US 2005-679425P	P	20050510		
	US 2005-679475P	P	20050510		

```
     US 2005-679511P      P     20050510
     US 2005-679512P      P     20050510
     US 2005-680097P      P     20050512
     US 2005-681398P      P     20050516
     US 2005-702349P      P     20050725
     US 2005-712311P      P     20050829
     US 2005-712459P      P     20050829
     US 2005-715079P      P     20050908
     US 2005-715099P      P     20050908
     US 2006-432228       A2    20060510
     US 2007-706932       A2    20070213
OS   MARPAT 147:462234

L1   ANSWER 2 OF 55  CA  COPYRIGHT 2007 ACS on STN
AN   147:53098  CA
TI   Preparation of antibacterial 4,5-substituted aminoglycoside
     analogs for use as prophylactic or therapeutics against microbial
     infection
IN   Swayze, Eric E.; Hanessian, Stephen; Szychowski, Janek; Adhikari, Susanta
     Sekhar; Pachamuthu, Kandasamy; Wang, Xiaojing; Migawa, Michael T.;
     Griffey, Richard H.
PA   Isis Pharmaceuticals, Inc., USA
SO   PCT Int. Appl., 164pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2007064954         A2    20070607    WO 2006-US46122         20061201
     WO 2007064954         A3    20070816
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
             KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,
             MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
             RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRAI US 2005-742051P      P     20051202
OS   MARPAT 147:53098

L1   ANSWER 3 OF 55  CA  COPYRIGHT 2007 ACS on STN
AN   144:488901  CA
TI   Preparation of macrolone erythromycin ketolide derivatives as
     antibacterial agents
IN   Best, Desmond, John; Elder, John, Stephen; Fajdetic, Andrea; Forrest,
     Andrew, Keith; Sheppard, Robert, John
PA   Glaxo Group Limited, UK; Pliva-Istrazivacki Institut D.O.O.
SO   PCT Int. Appl., 130 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 3
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2006050942         A1    20060518    WO 2005-EP12038         20051109
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
```

KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

AU	2005303961	A1	20060518	AU 2005-303961	20051109
CA	2587413	A1	20060518	CA 2005-2587413	20051109
EP	1824870	A1	20070829	EP 2005-801894	20051109

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR

WO	2007054295	A1	20070518	WO 2006-EP10731	20061107

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,
MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

WO	2007054296	A1	20070518	WO 2006-EP10733	20061107

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,
MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

IN	2007DN03539	A	20070831	IN 2007-DN3539	20070511
NO	2007002939	A	20070808	NO 2007-2939	20070608
PRAI GB	2004-24959	A	20041111		
WO	2005-EP12038	W	20051109		
GB	2006-9373	A	20060511		

OS MARPAT 144:488901
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 4 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 144:468396 CA
TI Preparation of macrolone erythromycin ketolide derivatives as antibacterial agents
IN Alihodzic, Sulejman; Frydrych, Catherine Simone Victoire; Hunt, Eric
PA Glaxo Group Limited, UK; Pliva-Istrazivacki Institut D.O.O.
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006050943	A1	20060518	WO 2005-EP12039	20051109

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1824497 A1 20070829 EP 2005-811076 20051109

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR

PRAI GB 2004-24961 A 20041111

WO 2005-EP12039 W 20051109

OS MARPAT 144:468396

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 5 OF 55 CA COPYRIGHT 2007 ACS on STN

AN 144:450873 CA

TI Preparation of macrolone erythromycin ketolide derivatives as antibacterial agents

IN Frydrych, Catherine, Simone, Victoire

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 84 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006050941	A1	20060518	WO 2005-EP12037	20051109

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1824869 A1 20070829 EP 2005-801631 20051109

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR

PRAI GB 2004-24958 A 20041111

WO 2005-EP12037 W 20051109

OS MARPAT 144:450873

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 6 OF 55 CA COPYRIGHT 2007 ACS on STN

AN 144:331660 CA

TI Preparation of macrolide bicyclic 9a-azalide erythromycin derivatives as antibacterial agents

IN Or, Yat Sun; Qiu, Yao-Ling; Wang, Guoqiang; Niu, Deqiang; Phan, Ly Tam

PA USA

SO U.S. Pat. Appl. Publ., 65 pp.
CODEN: USXXCO

DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006069048	A1	20060330	US 2005-236043	20050927
	WO 2006039263	A2	20060413	WO 2005-US34578	20050928
	WO 2006039263	A3	20060720		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2004-614171P P 20040929
US 2005-236043 A 20050927
OS CASREACT 144:331660; MARPAT 144:331660

L1 ANSWER 7 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 144:51834 CA
TI Preparation of macrocyclic desmycocin amino glycosides useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic therapeutic agents
IN Chen, Yi; Farmer, Jay J.; Sutcliffe, Joyce A.; Bhattacharjee, Ashoke
PA Rib-X Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005118610	A2	20051215	WO 2005-US18733	20050527
	WO 2005118610	A3	20061019		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	WO 2005085266	A2	20050915	WO 2005-US6082	20050225
	WO 2005085266	A3	20060105		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2004-575949P P 20040601
WO 2005-US6082 A 20050225
US 2004-548280P P 20040227
OS MARPAT 144:51834

L1 ANSWER 8 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 143:478161 CA
TI Preparation of azithromycin and erythromycin macrolides substituted at the 4'-position as antibacterial agents
IN Alihodzic, Sulejman; Mutak, Stjepan; Palej, Ivana
PA Pliva-Istrazivacki Institut D.O.O., Croatia
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005108413	A1	20051117	WO 2005-IB1203	20050503
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2566112	A1	20051117	CA 2005-2566112	20050503
EP 1756134	A1	20070228	EP 2005-734891	20050503
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1980945	A	20070613	CN 2005-80023022	20050503
IN 2006DN06104	A	20070831	IN 2006-DN6104	20061019
PRAI US 2004-569377P	P	20040506		
US 2004-582106P	P	20040622		
WO 2005-IB1203	W	20050503		

OS MARPAT 143:478161
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 9 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 143:460388 CA
TI Preparation of azithromycin and erythromycin macrolides substituted at the 4'-position as antibacterial agents
IN Alihodzic, Sulejman; Mutak, Stjepan; Pavlovic, Drazen; Palej, Ivana; Stimac, Vlado; Kapic, Samra; Zupan, Adrijana; Matanovic, Maja
PA Pliva-Istrazivacki Institut D.O.O., Croatia
SO PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005108412	A1	20051117	WO 2005-IB1186	20050502
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,				

NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2005240849	A1	20051117	AU 2005-240849	20050502
CA	2566085	A1	20051117	CA 2005-2566085	20050502
EP	1756135	A1	20070228	EP 2005-739739	20050502

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU

BR	2005010328	A	20071023	BR 2005-10328	20050502
CN	101068824	A	20071107	CN 2005-80022944	20050502
KR	2007031900	A	20070320	KR 2006-723254	20061106
NO	2006005662	A	20070116	NO 2006-5662	20061206
PRAI	US 2004-569402P	P	20040506		
	US 2004-581118P	P	20040618		
	WO 2005-IB1186	W	20050502		

OS MARPAT 143:460388

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 10 OF 55 CA COPYRIGHT 2007 ACS on STN

AN 143:306499 CA

TI Preparation of macrocyclic azithromycin compounds as antibacterial, anti-proliferative, and antiinflammatory agents

IN Farmer, Jay J.; Bhattacharjee, Ashoke; Chen, Yi; Goldberg, Joel A.; Ippolito, Joseph A.; Kanyo, Zoltan F.; Lou, Rongliang; Oyelere, Adegboyega K.; Sherer, Edward C.; Sutcliffe, Joyce A.; Wang, Deping; Wu, Yusheng; Du, Yanming

PA Rib-X Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 333 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005085266	A2	20050915	WO 2005-US6082	20050225
WO 2005085266	A3	20060105		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP	1723159	A2	20061122	EP 2005-723790	20050225

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

CN	1950388	A	20070418	CN 2005-80013532	20050225
JP	2007525520	T	20070906	JP 2007-501005	20050225
WO	2005118610	A2	20051215	WO 2005-US18733	20050527
WO	2005118610	A3	20061019		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

	IN 2006KN02592	A	20070601	IN 2006-KN2592	20060908
PRAI	US 2004-548280P	P	20040227		
	US 2004-575949P	P	20040601		
	WO 2005-US6082	W	20050225		

OS MARPAT 143:306499

L1 ANSWER 11 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 142:355522 CA
TI Preparation of macrolide 9a,11-3C-bicyclic 9a-azalide erythromycin analogs as prodrug antibacterial agents
IN Wang, Guoqiang; Peng, Yulin; Wang, Yanchun; Phan, Ly Tam; Or, Yat Sun
PA Enanta Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005030227	A1	20050407	WO 2004-US30780	20040921

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

	US 2005090460	A1	20050428	US 2004-946339	20040921
	US 7276487	B2	20071002		
PRAI	US 2003-560735P	P	20030923		

OS MARPAT 142:355522
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 12 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 142:240672 CA
TI Preparation of N-des-methyl-N-substituted-11-deoxy-erythromycin macrolides as antibacterial and pro-kinetic agents and can be used to treat disorders of gastric motility
IN Carreras, Christopher; Liu, Yaoquan
PA Kosan Biosciences, Inc., USA
SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005018576	A2	20050303	WO 2004-US27854	20040825
WO 2005018576	A3	20051215		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

	US 2005119195	A1	20050602	US 2004-926170	20040824
	CA 2533583	A1	20050303	CA 2004-2533583	20040825
	EP 1658301	A2	20060524	EP 2004-782351	20040825
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007521320	T	20070802	JP 2006-524876	20040825
PRAI	US 2003-498108P	P	20030826		
	US 2004-920170	A	20040824		
	WO 2004-US27854	W	20040825		

OS CASREACT 142:240672; MARPAT 142:240672

L1 ANSWER 13 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 142:38480 CA
TI Preparation of 11-12-bicyclic erythromycin macrolides as antibacterial agents
IN Liu, Tongzhu; Phan, Ly Tam; Or, Yat Sun; Chen, Zhigang; Qiu, Yao-Ling
PA Enanta Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004108745	A2	20041216	WO 2004-US13042	20040428
	WO 2004108745	A3	20050224		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 6765016	B1	20040720	US 2003-455648	20030605
	US 6774115	B1	20040810	US 2003-454865	20030605
	US 2004254126	A1	20041216	US 2004-806748	20040323
PRAI	US 2003-454865	A	20030605		
	US 2003-455648	A	20030605		
	US 2004-455001	A	20040323		
	US 2004-806748	A	20040323		
	US 2003-455001	A2	20030605		
	US 2003-455219	A2	20030605		

OS MARPAT 142:38480

L1 ANSWER 14 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 142:38478 CA
TI Preparation of 11-12-bicyclic erythromycin macrolides as antibacterial agents
IN Qiu, Yao-Ling; Phan, Ly Tam; Chen, Zhigang; Liu, Tongzhu; Or, Yat Sun
PA USA

SO U.S. Pat. Appl. Publ., 52 pp., Cont.-in-part of U.S. Ser. No. 455,219.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004254126	A1	20041216	US 2004-806748	20040323
	US 6716820	B1	20040406	US 2003-455001	20030605
	US 6765016	B1	20040720	US 2003-455648	20030605
	US 6774115	B1	20040810	US 2003-454865	20030605
	US 6790835	B1	20040914	US 2003-455219	20030605
	WO 2004108745	A2	20041216	WO 2004-US13042	20040428
	WO 2004108745	A3	20050224		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004245479	A1	20041216	AU 2004-245479	20040517
	CA 2531561	A1	20041216	CA 2004-2531561	20040517
	WO 2004108746	A2	20041216	WO 2004-US15491	20040517
	WO 2004108746	A3	20050414		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1646638	A2	20060419	EP 2004-785698	20040517
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI	US 2003-454865	A2	20030605		
	US 2003-455001	A2	20030605		
	US 2003-455219	A2	20030605		
	US 2003-455648	A2	20030605		
	US 2004-455001	A	20040323		
	US 2004-806748	A	20040323		
	WO 2004-US15491	W	20040517		

OS MARPAT 142:38478

L1 ANSWER 15 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 142:6762 CA
TI Preparation of azithromycin macrolides substituted at the 4"-position as antibacterial agents
IN Alihodzic, Sulejman; Berdik, Andrea; Jarvest, Richard Lewis; Lazarevski, Gorjana
PA Glaxo Group Limited, UK; Pliva-Istrazivacki Institut D.O.O.
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004101590	A1	20041125	WO 2004-EP5086	20040511
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2525459	A1	20041125	CA 2004-2525459	20040511
	EP 1633765	A1	20060315	EP 2004-732099	20040511
	EP 1633765	B1	20071114		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1820016	A	20060816	CN 2004-80019644	20040511
	JP 2006528668	T	20061221	JP 2006-529797	20040511
	IN 2005KN02188	A	20060929	IN 2005-KN2188	20051107
PRAI	GB 2003-10992	A	20030513		
	WO 2004-EP5086	W	20040511		

OS MARPAT 142:6762
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 16 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 142:6758 CA
TI Preparation of azithromycin and erythromycin macrolides substituted at the 4"-position as antibacterial agents
IN Alihodzic, Sulejman; Forrest, Andrew Keith; Jarvest, Richard Lewis; Lazarevski, Gorjana; Pavlovic, Drazen
PA Glaxo Group Limited, UK; Pliva-Istrazivacki Institut D.O.O.
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004101586	A1	20041125	WO 2004-EP5082	20040511
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004238528	A1	20041125	AU 2004-238528	20040511
	CA 2525452	A1	20041125	CA 2004-2525452	20040511
	EP 1628988	A1	20060301	EP 2004-732102	20040511
	EP 1628988	B1	20061004		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004010246	A	20060516	BR 2004-10246	20040511
	AT 341560	T	20061015	AT 2004-732102	20040511
	CN 1849328	A	20061018	CN 2004-80019264	20040511
	JP 2007502313	T	20070208	JP 2006-529794	20040511

	ES 2273255	T3	20070501	ES 2004-4732102	20040511
	IN 2005KN02197	A	20060922	IN 2005-KN2197	20051107
	MX 2005PA12163	A	20060519	MX 2005-PA12163	20051111
	US 2007185117	A1	20070809	US 2007-556645	20070315
PRAI	GB 2003-10986	A	20030513		
	WO 2004-EP5082	W	20040511		

OS MARPAT 142:6758
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 17 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 142:6757 CA
TI Preparation of azithromycin and erythromycin macrolides substituted at the 4'-position as antibacterial agents
IN Alihodzic, Sulejman; Berdik, Andrea; Berge, John Michael; Jarvest, Richard Lewis; Mutak, Stjepan
PA Glaxo Group Limited, UK; Pliva-Istrazivacki Institut D.O.O.
SO PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004101585	A1	20041125	WO 2004-EP5081	20040511
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2525449	A1	20041125	CA 2004-2525449	20040511
	EP 1625137	A1	20060215	EP 2004-732089	20040511
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1820017	A	20060816	CN 2004-80019655	20040511
	JP 2006528947	T	20061228	JP 2006-529793	20040511
	IN 2005KN02194	A	20060929	IN 2005-KN2194	20051107
	US 2007213283	A1	20070913	US 2006-556381	20061213
PRAI	GB 2003-10984	A	20030513		
	WO 2004-EP5081	W	20040511		

OS MARPAT 142:6757
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 18 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 142:6756 CA
TI Preparation of macrolide glycosides substituted at the 3-position having antibacterial activity
IN Jarvest, Richard Lewis
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004101584	A1	20041125	WO 2004-EP5080	20040511

```
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
PRAI GB 2003-10981        A     20030513
OS   MARPAT 142:6756
RE.CNT  2     THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1   ANSWER 19 OF 55  CA  COPYRIGHT 2007 ACS on STN
AN   141:411193  CA
TI   Preparation of macrolide pyridyl substituted erythromycin ketolide analogs
     as antibiotics
IN   Burger, Matthew; Carroll, Georgia; Chu, Daniel; Lin, Xiaodong; Plattner,
     Jacob; Rico, Alice
PA   Chiron Corporation, USA
SO   PCT Int. Appl., 358 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2004096822         A2    20041111    WO 2004-US12645         20040423
     WO 2004096822         A3    20041216
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
             SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
             TD, TG
     CA 2523134            A1    20041111    CA 2004-2523134         20040423
     US 2005009764         A1    20050113    US 2004-831749          20040423
     EP 1618119            A2    20060125    EP 2004-750576          20040423
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
     JP 2006524702         T     20061102    JP 2006-513275          20040423
PRAI US 2003-465294P       P     20030425
     WO 2004-US12645       W     20040423
OS   MARPAT 141:411193

L1   ANSWER 20 OF 55  CA  COPYRIGHT 2007 ACS on STN
AN   141:406156  CA
TI   Methods for reducing oxidative stress in a cell with a sulfhydryl
     protected glutathione prodrug
IN   Nagasawa, Herbert T.; Cohen, Jonathan F.
PA   USA
SO   U.S. Pat. Appl. Publ., 12 pp.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 1
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004229815	A1	20041118	US 2003-750005	20031230
	AU 2004315267	A1	20050818	AU 2004-315267	20041227
	CA 2552285	A1	20050818	CA 2004-2552285	20041227
	WO 2005074903	A2	20050818	WO 2004-US43660	20041227
	WO 2005074903	A3	20060223		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1701732	A2	20060920	EP 2004-821314	20041227
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
	CN 1921876	A	20070228	CN 2004-80042221	20041227
	IN 2006MN00915	A	20070330	IN 2006-MN915	20060731
PRAI	US 2003-437872P	P	20030103		
	US 2003-750005	A	20031230		
	WO 2004-US43660	W	20041227		

L1 ANSWER 21 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 141:395758 CA
TI Preparation of amino sugars for treatment of anthrax infection using inhibitors of lethal factor protease activity
IN Goldman, Mark Evan; O'Malley, Sean; Simo, Ondrej; Nagata, Melissa; Jiao, Guan-Sheng; Hemscheidt, Klaus Thomas; Tang, Peng Cho; Cregar, Lynne
PA Hawaii Biotech, Inc., USA
SO PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004093821	A2	20041104	WO 2004-US13737	20040422
	WO 2004093821	A3	20051027		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-464923P	P	20030422		

L1 ANSWER 22 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 141:337861 CA
TI Medical device with a therapeutic agent such as paclitaxel
IN Paul, Ram H.; Sirota, Daniel J.; Amarant, Paul D.
PA Cook Incorporated, USA
SO U.S. Pat. Appl. Publ., 17 pp.
CODEN: USXXCO

DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004210208	A1	20041021	US 2003-414939	20030416
PRAI US 2003-414939		20030416		

L1 ANSWER 23 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 141:243769 CA
TI Preparation of antibiotic 6-O-substituted bicyclic erythromycin macrolides as antibacterial agents
IN Qiu, Yao-ling; Phan, Ly Tam; Liu, Tongzhu; Chen, Zhigang; Or, Yat Sun
PA Enanta Pharmaceuticals, Inc., USA
SO U.S., 27 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6790835	B1	20040914	US 2003-455219	20030605
US 2004254126	A1	20041216	US 2004-806748	20040323
AU 2004245479	A1	20041216	AU 2004-245479	20040517
CA 2531561	A1	20041216	CA 2004-2531561	20040517
WO 2004108746	A2	20041216	WO 2004-US15491	20040517
WO 2004108746	A3	20050414		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1646638	A2	20060419	EP 2004-785698	20040517
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI US 2003-454865	A2	20030605		
US 2003-455001	A2	20030605		
US 2003-455219	A2	20030605		
US 2003-455648	A2	20030605		
US 2004-806748	A	20040323		
WO 2004-US15491	W	20040517		

OS CASREACT 141:243769; MARPAT 141:243769
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 24 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 141:89322 CA
TI Preparation of 6,11-4c-bicyclic 9a-azalide erythromycin derivatives as antibacterial agents
IN Wang, Guoqiang; Or, Yat Sun; Phan, Ly Tam
PA Enanta Pharmaceuticals, Inc., USA
SO U.S., 35 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 10

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
PI   US 6764998          B1    20040720    US 2003-464188        20030618
     CN 1910171          A     20070207    CN 2004-80040152      20040114
     US 2005009761       A1    20050113    US 2004-763377        20040123
     US 2005014707       A1    20050120    US 2004-840949        20040507
     WO 2005000863       A2    20050106    WO 2004-US15806       20040519
     WO 2005000863       A3    20050310
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     IN 2006DN03703      A     20070713    IN 2006-DN3703        20060628
PRAI US 2002-144396      B2    20020513
     US 2002-144558      B2    20020513
     US 2002-205018      A2    20020725
     US 2002-205357      A2    20020725
     US 2003-429485      A2    20030505
     US 2003-436622      A2    20030513
     US 2003-464188      A2    20030618
     WO 2004-US998       W     20040114
OS   MARPAT 141:89322
RE.CNT  13    THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1   ANSWER 25 OF 55  CA  COPYRIGHT 2007 ACS on STN
AN   141:54574  CA
TI   Preparation of aminodeoxy trisaccharides as prodrug
     antibacterial agents
IN   Cianci, Julia; Draffan, Alistair G.; Lambert, John N.; Nearn, Roland H.;
     Nguyen, Van T. T.
PA   Biota Scientific Management Pty. Ltd., Australia
SO   PCT Int. Appl., 83 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.       DATE
     --------------      ----   --------    --------------------  --------
PI   WO 2004050677        A1    20040617    WO 2003-AU1588        20031128
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
             NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003283127       A1    20040623    AU 2003-283127        20031128
     US 2006128608       A1    20060615    US 2005-536504        20051219
PRAI AU 2002-953095      A     20021129
     WO 2003-AU1588      W     20031128
RE.CNT  7     THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1   ANSWER 26 OF 55  CA  COPYRIGHT 2007 ACS on STN
AN   140:304027  CA
```

TI Preparation of macrolide anhydrolide erythromycin analogs as antibacterial agents
IN Vo, Nha Huu; Hou, Ying; Phan, Ly Tam; Or, Yat Sun
PA Enanta Pharmaceuticals, Inc., USA
SO U.S., 13 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6720308	B1	20040413	US 2002-289820	20021107
	WO 2004069854	A1	20040819	WO 2003-US35697	20031107
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003290684	A1	20040830	AU 2003-290684	20031107
	US 2004220120	A1	20041104	US 2004-812501	20040330
PRAI	US 2002-289820	A	20021107		
	WO 2003-US35697	W	20031107		

OS MARPAT 140:304027
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 27 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:271146 CA
TI Preparation of antibiotic 6-O-substituted bicyclic erythromycin macrolides as antibacterial agents
IN Qiu, Yao-Ling; Phan, Ly Tam; Or, Yat Sun
PA Enanta Pharmaceuticals, Inc., USA
SO U.S., 21 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6716820	B1	20040406	US 2003-455001	20030605
	US 2004254126	A1	20041216	US 2004-806748	20040323
	AU 2004245479	A1	20041216	AU 2004-245479	20040517
	CA 2531561	A1	20041216	CA 2004-2531561	20040517
	WO 2004108746	A2	20041216	WO 2004-US15491	20040517
	WO 2004108746	A3	20050414		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1646638	A2	20060419	EP 2004-785698	20040517
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				

PRAI US 2003-454865 A2 20030605
US 2003-455001 A2 20030605
US 2003-455219 A2 20030605
US 2003-455648 A2 20030605
US 2004-806748 A 20040323
WO 2004-US15491 W 20040517
OS CASREACT 140:271146; MARPAT 140:271146
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 28 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:236004 CA
TI Preparation of 6,11-bicyclic erythromycin macrolides as antibacterial agents
IN Or, Yat Sun; Wang, Guoqiang; Phan, Ly Tam; Niu, Deqiang; Qiu, Yao-Ling; Vo, Nha Huu; Farmer, Jay Judson; Hou, Ying
PA USA
SO U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S. Ser. No. 144,396, abandoned.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004053861	A1	20040318	US 2003-436622	20030513
	US 7129221	B2	20061031		
	AU 2003229037	A1	20031111	AU 2003-229037	20030513
	AU 2003229037	B2	20070118		
	CA 2483875	A1	20031120	CA 2003-2483875	20030513
	EP 1509538	A1	20050302	EP 2003-726818	20030513
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1659178	A	20050824	CN 2003-813623	20030513
	JP 2005536465	T	20051202	JP 2004-503480	20030513
	NZ 536402	A	20060831	NZ 2003-536402	20030513
	US 2004171818	A1	20040902	US 2004-758409	20040114
	US 7022679	B2	20060404		
	WO 2005070918	A1	20050804	WO 2004-US998	20040114
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CN 1910171	A	20070207	CN 2004-80040152	20040114
	US 2005009761	A1	20050113	US 2004-763377	20040123
	US 2006058248	A1	20060316	US 2005-257680	20051025
	US 7135573	B2	20061114		
	IN 2006DN03703	A	20070713	IN 2006-DN3703	20060628
PRAI	US 2002-144396	B2	20020513		
	US 2002-144558	B2	20020513		
	US 2002-205018	A2	20020725		
	US 2002-205357	A2	20020725		
	US 2003-429485	A2	20030505		
	US 2003-436622	A	20030513		
	WO 2003-US14914	W	20030513		
	US 2003-464188	A2	20030618		
	US 2004-758409	A1	20040114		
	WO 2004-US998	W	20040114		

OS CASREACT 140:236004; MARPAT 140:236004
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 29 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:217956 CA
TI Preparation of motilide erythromycin compounds used in treatment of diseases characterized by impaired gastric motility
IN Santi, Daniel; Metcalf, Brian; Carreras, Christopher; Liu, Yaoquan; McDaniel, Robert; Rodriguez, Eduardo J.
PA Kosan Biosciences, Inc., USA
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004019879	A2	20040311	WO 2003-US26991	20030826
	WO 2004019879	A3	20040603		
	WO 2004019879	A8	20040729		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2492846	A1	20040311	CA 2003-2492846	20030826
	AU 2003273254	A1	20040319	AU 2003-273254	20030826
	US 2004138150	A1	20040715	US 2003-648946	20030826
	US 6946482	B2	20050920		
	EP 1532131	A2	20050525	EP 2003-755757	20030826
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1665799	A	20050907	CN 2003-815053	20030826
	JP 2005537317	T	20051208	JP 2004-531645	20030826
	IN 2005KN00210	A	20060609	IN 2005-KN210	20050217
PRAI	US 2002-407345P	P	20020829		
	WO 2003-US26991	W	20030826		

OS MARPAT 140:217956

L1 ANSWER 30 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:217887 CA
TI Antibiotic optimization via in vitro glycorandomization
AU Fu, Xun; Albermann, Christoph; Jiang, Jiqing; Liao, Jianchun; Zhang, Changsheng; Thorson, Jon S.
CS School of Pharmacy, Laboratory for Biosynthetic Chemistry, University of Wisconsin-Madison, Madison, WI, 53705, USA
SO Nature Biotechnology (2003), 21(12), 1467-1469
CODEN: NABIF9; ISSN: 1087-0156
PB Nature Publishing Group
DT Journal
LA English
OS CASREACT 140:217887
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 31 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:164138 CA
TI Preparation of antibacterial erythromycin derivatives with improved

pharmacokinetic profiles
IN Clark, Richard F.; Djuric, Stevan; Ma, Zhenkun; Phan, Ly; Rupp, Michael
PA USA
SO U.S. Pat. Appl. Publ., 16 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004033970	A1	20040219	US 2003-422111	20030424
	US 2005267054	A1	20051201	US 2005-167493	20050627
PRAI	US 2002-377001P	P	20020430		
	US 2003-422111	A1	20030424		

OS MARPAT 140:164138

L1 ANSWER 32 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:164136 CA
TI Preparation of tricyclic macrolide erythromycin derivatives as antibacterial agents
IN Gu, Yu-Gui; Ma, Zhenkun; Yong, Hong
PA USA
SO U.S. Pat. Appl. Publ., 46 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004029818	A1	20040212	US 2003-422401	20030424
	US 6992069	B2	20060131		
PRAI	US 2002-377008P	P	20020430		
	US 2002-398723P	P	20020726		

OS CASREACT 140:164136; MARPAT 140:164136
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 33 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:146397 CA
TI Preparation of 6,11-4-carbon bridged macrolide ketolides erythromycin analogs as antibacterial agents
IN Or, Yat Sun; Wang, Guogiang; Niu, Deqiang; Phan, Ly Tam
PA Enanta Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004011009	A1	20040205	WO 2003-US20860	20030701
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 6753318	B1	20040622	US 2002-205357	20020725
	AU 2003247706	A1	20040216	AU 2003-247706	20030701
	CN 1910171	A	20070207	CN 2004-80040152	20040114

	US 2005009763	A1	20050113	US 2004-841249	20040507
	IN 2006DN03703	A	20070713	IN 2006-DN3703	20060628
PRAI	US 2002-205357	A	20020725		
	WO 2003-US20860	W	20030701		
	WO 2004-US998	W	20040114		

OS CASREACT 140:146397; MARPAT 140:146397
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 34 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:146396 CA
TI Preparation of 6,11-4-carbon bridged macrolide ketolides erythromycin analogs as antibacterial agents
IN Or, Yat Sun; Wang, Guoqiang; Niu, Deqiang; Phan, Ly Tam
PA Enanra Pharmaceuticals, Inc., USA
SO U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004023895	A1	20040205	US 2002-205018	20020725
	US 6841664	B2	20050111		
	WO 2004011477	A2	20040205	WO 2003-US20864	20030601
	WO 2004011477	A3	20040318		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003281694	A1	20040216	AU 2003-281694	20030601
	CN 1910171	A	20070207	CN 2004-80040152	20040114
	US 2005009761	A1	20050113	US 2004-763377	20040123
	US 2004266998	A1	20041230	US 2004-841206	20040507
	US 7049417	B2	20060523		
	IN 2006DN03703	A	20070713	IN 2006-DN3703	20060628
PRAI	US 2002-144396	B2	20020513		
	US 2002-144558	B2	20020513		
	US 2002-205018	A	20020725		
	US 2002-205357	A2	20020725		
	US 2003-429485	A2	20030505		
	US 2003-436622	A2	20030513		
	WO 2003-US20864	W	20030601		
	US 2003-464188	A2	20030618		
	WO 2004-US998	W	20040114		

OS MARPAT 140:146396
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 35 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:111633 CA
TI Preparation of macrolide oxolide erythromycin derivatives as antibacterial agents
IN Ma, Zhenkun; Djuric, Stevan; Florjancic, Alan S.; Yong, Hong
PA USA
SO U.S. Pat. Appl. Publ., 36 pp.
CODEN: USXXCO
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004014688	A1	20040122	US 2003-420390	20030422
	US 6998390	B2	20060214		
PRAI	US 2002-375373P	P	20020425		

OS MARPAT 140:111633

L1 ANSWER 36 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:94231 CA
TI Preparation of 11-deoxy-azalide erythromycin macrolide derivatives as prodrug antibacterial agents
IN Clark, Richard; Djuric, Stevan; Ma, Zhenkun; Wang, Sanyi
PA Abbott Laboratories, USA
SO U.S. Pat. Appl. Publ., 16 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004014953	A1	20040122	US 2003-421577	20030423
	US 6933283	B2	20050823		
PRAI	US 2002-375325P	P	20020425		

OS MARPAT 140:94231
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 37 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:77362 CA
TI Preparation of macrolide erythromycin antibacterial compounds with activity against penicillin-resistant Streptococcus pneumoniae
IN Phelan, Kathleen; Djuric, Stevan; Ma, Zhenkun; Marron, Thomas; Yong, Hong; Zanze, Irini
PA USA
SO U.S. Pat. Appl. Publ., 12 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004009932	A1	20040115	US 2003-421460	20030423
PRAI	US 2002-375652P	P	20020426		

OS MARPAT 140:77362

L1 ANSWER 38 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:77361 CA
TI Preparation of macrolide erythromycin derivatives as antibacterial agents
IN Clark, Richard; Djuric, Stevan; Ma, Zhenkun; Wang, Sanyi
PA Abbott Laboratories, USA
SO U.S. Pat. Appl. Publ., 24 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004009931	A1	20040115	US 2003-361221	20030210
	US 6831068	B2	20041214		
PRAI	US 2002-356296P	P	20020213		

OS MARPAT 140:77361
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 39 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:59899 CA
TI Preparation of antibiotic macrolide erythromycin 11-C-substituted ketolides as antibacterial agents
IN Phan, Ly Tam; Farmer, Jay Judson; Or, Yat Sun
PA Enanta Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004000864	A2	20031231	WO 2003-US20126	20030625
	WO 2004000864	A3	20040226		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004002464	A1	20040101	US 2002-179590	20020625
	US 6750204	B2	20040615		
	AU 2003243789	A1	20040106	AU 2003-243789	20030625
PRAI	US 2002-179590	A	20020625		
	WO 2003-US20126	W	20030625		

OS MARPAT 140:59899

L1 ANSWER 40 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:16930 CA
TI Preparation of 3-descladinosyl-6-O-carbamoyl and 6-O-carbonoyl erythromycin macrolides as antibacterial agents
IN Henninger, Todd C.; Macielag, Mark J.; Marinelli, Brett A.; Zhu, Bin
PA Janssen Pharmaceutica N.V., Belg.
SO PCT Int. Appl., 179 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003102010	A1	20031211	WO 2003-US16617	20030528
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2487918	A1	20031211	CA 2003-2487918	20030528
	AU 2003234650	A1	20031219	AU 2003-234650	20030528
	US 2004018994	A1	20040129	US 2003-447058	20030528
	US 6825172	B2	20041130		
	EP 1513856	A1	20050316	EP 2003-729151	20030528
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

	CN 1671726	A	20050921	CN 2003-817759	20030528
	JP 2005531603	T	20051020	JP 2004-509701	20030528
PRAI	US 2002-384483P	P	20020531		
	WO 2003-US16617	W	20030528		

OS MARPAT 140:16930
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 41 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 139:396138 CA
TI Preparation of 6,11-bicyclic erythromycin macrolides as antibacterial agents
IN Or, Yat Sun; Wang, Guoqiang; Phan, Ly Tam; Niu, Deqiang; Qui, Yao-Ling; Vo, Nha Huu; Farmer, Jay Judson; Hou, Ying
PA Enanta Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003095466	A1	20031120	WO 2003-US14914	20030513
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003229037	A1	20031111	AU 2003-229037	20030513
	AU 2003229037	B2	20070118		
	CA 2483875	A1	20031120	CA 2003-2483875	20030513
	EP 1509538	A1	20050302	EP 2003-726818	20030513
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005536465	T	20051202	JP 2004-503480	20030513
	NZ 536402	A	20060831	NZ 2003-536402	20030513
	WO 2005070918	A1	20050804	WO 2004-US998	20040114
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CN 1910171	A	20070207	CN 2004-80040152	20040114
	IN 2006DN03703	A	20070713	IN 2006-DN3703	20060628
PRAI	US 2002-144396	A	20020513		
	US 2003-436622	A	20030513		
	WO 2003-US14914	W	20030513		
	WO 2004-US998	W	20040114		

OS CASREACT 139:396138; MARPAT 139:396138
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 42 OF 55 CA COPYRIGHT 2007 ACS on STN

AN 139:381701 CA
TI Preparation of antibacterial erythromycin derivatives with improved pharmacokinetic profiles
IN Clark, Richard F.; Djuric, Stevan M.; Ma, Zhenkun; Phan, Ly; Rupp, Michael J.
PA Abbott Laboratories, USA
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003093288	A1	20031113	WO 2003-US12970	20030425
	W: CA, JP, MX				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
	US 2003207820	A1	20031106	US 2002-136715	20020430
	CA 2484087	A1	20031113	CA 2003-2484087	20030425
	EP 1501845	A1	20050202	EP 2003-721887	20030425
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
	JP 2005529143	T	20050929	JP 2004-501427	20030425
	MX 2004PA10802	A	20050307	MX 2004-PA10802	20041029
PRAI	US 2002-136715	A	20020430		
	US 2003-422384	A	20030424		
	WO 2003-US12970	W	20030425		

OS MARPAT 139:381701
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 43 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 139:365175 CA
TI Preparation of tricyclic macrolide erythromycin derivatives as antibacterial agents
IN Gu, Yugui; Ma, Zhenkun; Yong, Hong
PA Abbott Laboratories, USA
SO PCT Int. Appl., 141 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003093289	A1	20031113	WO 2003-US12971	20030425
	W: CA, JP, MX				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
	CA 2484095	A1	20031113	CA 2003-2484095	20030425
	EP 1501846	A1	20050202	EP 2003-731049	20030425
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
	JP 2005530758	T	20051013	JP 2004-501428	20030425
	MX 2004PA10818	A	20050307	MX 2004-PA10818	20041029
PRAI	US 2002-136796	A	20020430		
	US 2002-205708	A	20020726		
	US 2003-422309	A	20030424		
	WO 2003-US12971	W	20030425		

OS CASREACT 139:365175; MARPAT 139:365175
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 44 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 139:365174 CA

TI Preparation of 6,11-3c-bicyclic 9a-azalide erythromycin derivatives as antibacterial agents
IN Wang, Guoqiang; Or, Yat Sun; Phan, Ly Tam; Busuyek, Marina
PA Enanta Pharmaceuticals, Inc., USA
SO U.S., 29 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6645941	B1	20031111	US 2003-397923	20030326
WO 2004087728	A2	20041014	WO 2004-US8940	20040324
WO 2004087728	A3	20041216		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-397923 A 20030326
OS CASREACT 139:365174; MARPAT 139:365174
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 45 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 139:365172 CA
TI Preparation of erythromycin 9-oxime macrolides as antibacterial agents
IN Searle, Xenia Beebe; Djuric, Stevan; Ma, Zhenkun; Yang, Fan
PA Abbott Laboratories, USA
SO PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003090761	A1	20031106	WO 2003-US12478	20030423
W: CA, JP, MX				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2483221	A1	20031106	CA 2003-2483221	20030423
EP 1501519	A1	20050202	EP 2003-719894	20030423
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006513976	T	20060427	JP 2003-587394	20030423
MX 2004PA10558	A	20050930	MX 2004-PA10558	20041025

PRAI US 2002-131851 A 20020425
US 2003-420260 A 20030422
US 2003-420391 A 20030422
WO 2003-US12478 W 20030423
OS MARPAT 139:365172
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 46 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 139:365171 CA
TI Preparation of macrolide oxolide erythromycin derivatives as antibacterial agents

IN Ma, Zhenkun; Djuric, Stevan; Florjancic, Alan S.; Yong, Hong; Gu, Yugui
PA Abbott Laboratories, USA
SO PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003090760	A1	20031106	WO 2003-US12461	20030423
	W: CA, JP, MX				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
	CA 2483220	A1	20031106	CA 2003-2483220	20030423
	EP 1499326	A1	20050126	EP 2003-719889	20030423
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005528409	T	20050922	JP 2003-587393	20030423
	EP 1579864	A1	20050928	EP 2005-104506	20030423
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	MX 2004PA10556	A	20050217	MX 2004-PA10556	20041025
PRAI	US 2002-132121	A	20020425		
	US 2003-420257	A	20030422		
	EP 2003-719889	A3	20030423		
	WO 2003-US12461	W	20030423		

OS MARPAT 139:365171
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 47 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 139:365170 CA
TI Preparation of 11-deoxy-azalide erythromycin macrolide derivatives as prodrug antibacterial agents
IN Clark, Richard; Djuric, Stevan; Ma, Zhenkun; Wang, Sanyi
PA Abbott Laboratories, USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003090679	A2	20031106	WO 2003-US12590	20030424
	WO 2003090679	A3	20040311		
	W: CA, JP, MX				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
	CA 2483281	A1	20031106	CA 2003-2483281	20030424
	EP 1501847	A2	20050202	EP 2003-733878	20030424
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005529884	T	20051006	JP 2003-587318	20030424
	MX 2004PA10557	A	20050217	MX 2004-PA10557	20041025
PRAI	US 2002-132036	A	20020425		
	US 2003-421091	A	20030423		
	WO 2003-US12590	W	20030424		

OS MARPAT 139:365170

L1 ANSWER 48 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 139:350908 CA
TI Preparation of antibacterial erythromycin derivatives with improved pharmacokinetic profiles
IN Clark, Richard F.; Djuric, Stevan; Ma, Zhenkun; Phan, Ly; Rupp, Michael

PA USA
SO U.S. Pat. Appl. Publ., 13 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003207820	A1	20031106	US 2002-136715	20020430
	CA 2484087	A1	20031113	CA 2003-2484087	20030425
	WO 2003093288	A1	20031113	WO 2003-US12970	20030425
	W: CA, JP, MX				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
	EP 1501845	A1	20050202	EP 2003-721887	20030425
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
	JP 2005529143	T	20050929	JP 2004-501427	20030425
	MX 2004PA10802	A	20050307	MX 2004-PA10802	20041029
PRAI	US 2002-136715	A	20020430		
	US 2003-422384	A	20030424		
	WO 2003-US12970	W	20030425		

OS MARPAT 139:350908

L1 ANSWER 49 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 139:338165 CA
TI Preparation of macrolide substituted 5-O-mycaminosyltylonide derivatives as antibacterial agents
IN Phan, Ly Tam; Vo, Nha Huu; Or, Yat Sun; Qiu, Yao-Ling; Hou, Ying
PA Enanta Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003089447	A1	20031030	WO 2003-US12040	20030418
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003203858	A1	20031030	US 2002-125840	20020419
	US 6710034	B2	20040323		
	AU 2003234131	A1	20031103	AU 2003-234131	20030418
	US 2004235760	A1	20041125	US 2004-796412	20040309
PRAI	US 2002-125840	A	20020419		
	WO 2003-US12040	W	20030418		

OS CASREACT 139:338165; MARPAT 139:338165
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 50 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 139:338164 CA
TI Preparation of macrolide 23-O-substituted 5-O-mycaminosyltylonide derivatives as antibacterial agents
IN Phan, Ly Tam; Qiu, Yao-Ling; Or, Yat Sun; Vo, Nha Huu; Jian, Tianying; Hou, Ying; Busuyek, Marina

PA Enanta Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003089446	A2	20031030	WO 2003-US12211	20030418
	WO 2003089446	A3	20031218		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003212010	A1	20031113	US 2002-126076	20020419
	US 6753415	B2	20040622		
	AU 2003222659	A1	20031103	AU 2003-222659	20030418
	US 2005020823	A1	20050127	US 2004-840948	20040507
PRAI	US 2002-126076	A	20020419		
	WO 2003-US12211	W	20030418		

OS CASREACT 139:338164; MARPAT 139:338164

L1 ANSWER 51 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 137:210903 CA
TI Use of 5-substituted nucleosides and/or prodrugs thereof in combination preparations for the resistance-free treatment of infectious diseases
IN Fahrig, Rudolf Hinrich Hermann; Sonntag, Denise
PA Resprotect G.m.b.H., Germany
SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002067951	A2	20020906	WO 2002-EP1890	20020222
	WO 2002067951	A3	20030320		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10108851	A1	20020912	DE 2001-10108851	20010223
	AU 2002234644	A1	20020912	AU 2002-234644	20020222
	EP 1368040	A2	20031210	EP 2002-701291	20020222
	EP 1368040	B1	20060705		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004526713	T	20040902	JP 2002-567317	20020222
	AT 332141	T	20060715	AT 2002-701291	20020222
	US 2004127454	A1	20040701	US 2004-468017	20040204
	US 7122528	B2	20061017		
PRAI	DE 2001-10108851	A	20010223		
	WO 2002-EP1890	W	20020222		

L1 ANSWER 52 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 136:156403 CA
TI Methods for identifying therapeutic targets for treating infectious disease
IN Shepard, Michael H.; Lackey, David B.; Cathers, Brian E.; Sergeeva, Maria V.
PA Newbiotics, Inc., USA
SO PCT Int. Appl., 503 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002007780	A2	20020131	WO 2001-US23095	20010720
	WO 2002007780	A3	20030220		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001077093	A5	20020205	AU 2001-77093	20010720
	US 2003130179	A1	20030710	US 2001-910345	20010720
PRAI	US 2000-219598P	P	20000720		
	US 2000-244953P	P	20001101		
	US 2001-276728P	P	20010316		
	WO 2001-US23095	W	20010720		

L1 ANSWER 53 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 135:195449 CA
TI Coumarin derivatives as P-glycoprotein inhibitors for enhancing the antimicrobial and antitumor activities of other antimicrobial and cytotoxic agents
IN Gumbleton, Mark; Abulrob, Abedel-nasser; Russell, Allan Denver; Simons, Claire
PA University College Cardiff Consultants Limited, UK
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001060827	A1	20010823	WO 2001-GB689	20010219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	GB 2000-3685	A	20000217		

OS MARPAT 135:195449
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 54 OF 55 CA COPYRIGHT 2007 ACS on STN

AN 133:115890 CA
TI Selection of prodrug activating enzyme coding genes using bacteriophage library transformation of lysogenic bacteria
IN Searle, Peter F.
PA Cobra Therapeutics Limited, UK
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000043541	A1	20000727	WO 2000-GB157	20000121
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2358944	A1	20000727	CA 2000-2358944	20000121
	EP 1147218	A1	20011024	EP 2000-900727	20000121
	EP 1147218	B1	20050316		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	AT 291099	T	20050415	AT 2000-900727	20000121
	US 2002123037	A1	20020905	US 2001-889761	20011106
PRAI	GB 1999-1471	A	19990122		
	US 1999-116924P	P	19990122		
	WO 2000-GB157	W	20000121		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 55 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 125:104145 CA
TI New model of oropharyngeal and gastrointestinal colonization by Candida albicans in CD4+ T-cell-deficient mice for evaluation of antifungal agents
AU Flattery, Amy M.; Abruzzo, George K.; Gill, Charles J.; Smith, Jeffrey G.; Bartizal, Ken
CS Antibiotic Discovery and Development, Merck Research laboratories, Rahway, NJ, 07065-0900, USA
SO Antimicrobial Agents and Chemotherapy (1996), 40(7), 1604-1609
CODEN: AMACCQ; ISSN: 0066-4804
PB American Society for Microbiology
DT Journal
LA English

=> d l1 1-55 an ab

L1 ANSWER 1 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 147:462234 CA
AB The invention discloses methods using antimicrobial compds. for preventing or reducing the risk of infection due to surgical or invasive medical procedures.

L1 ANSWER 2 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 147:53098 CA
AB Antibacterial 4,5-substituted aminoglycoside analogs I, wherein Q1 is azido, OH, protected OH, (un)substituted amino, or heterocyclic ring systems; Q2 is an (un)substituted amino group; Q3 and Q4 are independently OH, protected hydroxyl, or an (un)substituted alkyl group; Q5 is H, halo, cyano, azido, ether, (un)substituted amino, protected amino, or a

heterocyclic ring system; Z1 and Z2 are independently H, hydroxyl or a protected hydroxyl group; Z3 is an O-linked aminoglycosides with (un)protected amino or hydroxyl substituents are prepared as prophylactic or therapeutics against microbial infection. Thus, II was prepared in 80% yield and shown to prevent lethal bacterial infections in mice (0.5 mg/kg resulted in no dead mice at 10% mucin). Further, I can be successfully employed as therapeutic prodrugs in the treatment of bacterial infection from sources such as S. pyogenes, E. coli, S. aureus, E. faecalis, K. pneumoniae and P. vulgaris.

L1 ANSWER 3 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 144:488901 CA
AB Macrolone erythromycin ketolide derivs. I, wherein A is a bivalent radical CO, amino-alkylidene, alkylidene-amino, imine; A and R4 taken together with the intervening atoms form a cyclic group, sugar residue; R1 is a sugar residue; R2 is H, hydroxyl group; R3 is H, alkyl, alkenyl; R4 is OH, alkenyl-oxy; R5 is OH; R5 and R5 taken together with the intervening atoms form a cyclic group; R6 is H, F; were prepared and used in therapy as antibacterial agents. Thus, macrolide II was prepared and tested as antibacterial agent. The compds. in the above examples gave min. inhibitory concns. (MICs) less than 1 μg per mL against erythromycin-sensitive and erythromycin-resistant strains of Streptococcus pneumoniae and Streptococcus pyogenes.

L1 ANSWER 4 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 144:468396 CA
AB Macrolone erythromycin ketolide derivs. I, wherein A is a bivalent radical CO, amino-alkylidene, alkylidene-amino, imine; A and R4 taken together with the intervening atoms form a cyclic group, sugar residue; R1 is a sugar residue; R2 is H, hydroxyl group; R3 is H, alkyl, alkenyl; R4 is OH, alkenyl-oxy; R5 is OH; R5 and R5 taken together with the intervening atoms form a cyclic group; R6 is H, F; were prepared and used in therapy as antibacterial agents. Thus, macrolide II was prepared and tested as antibacterial agent. The compds. in the above examples gave min. inhibitory concns. (MICs) less than 1 μg per mL against erythromycin-sensitive and erythromycin-resistant strains of Streptococcus pneumoniae and Streptococcus pyogenes.

L1 ANSWER 5 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 144:450873 CA
AB Macrolone erythromycin ketolide derivs. I, wherein A is a bivalent radical CO, amino-alkylidene, alkylidene-amino, imine; A and R4 taken together with the intervening atoms form a cyclic group, sugar residue; R1 is a sugar residue; R2 is H, hydroxyl group; R3 is H, alkyl, alkenyl; R4 is OH, alkenyl-oxy; R5 is OH; R5 and R5 taken together with the intervening atoms form a cyclic group; R6 is H, F; were prepared and used in therapy as antibacterial agents. Thus, macrolide II was prepared and tested as antibacterial agent. The compds. in the above examples gave min. inhibitory concns. (MICs) less than 1 μg per mL against erythromycin-sensitive and erythromycin-resistant strains of Streptococcus pneumoniae and Streptococcus pyogenes.

L1 ANSWER 6 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 144:331660 CA
AB Macrolide bicyclic 9a-azalide erythromycin derivs. I and II, wherein V is substituted alkylidene, cyclo-alkylidene; G and W are independently H, alkyl, alkenyl, alkynyl, acyl, ester, amide; L is Et, CH(OH)Me, alkyl, alkenyl, alkynyl, D is amino-alkylidene, amino-acyl, imino, R is H, hydroxy protecting group; were prepared and tested as antibacterial agents. Thus, macrolide II (V = CH2CH:CHCH2, G = W = Y = Z = H, L = Et, R = Ac) was prepared and tested in vitro as antibacterial agent. The compds. of the invention generally demonstrated an MIC in the range from about 64 μg/mL to about 0.03 μg/mL.

L1 ANSWER 7 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 144:51834 CA
AB The present invention provides macrocyclic desmycocin amino glycosides I and II, wherein T is macrolide; R1 and R3 are independently H, alkyl, alkenyl, alkynyl, acyl ester, amide, thio-acyl, thio-ester, thio-amide; R2 and R4 are H, alkoxy; D is single bond, alkyl, alkenyl,alkynyl, acyl, ester, amide, imine, sulfonyl, amine, thio-acyl, thio-amide; E is aromatic heterocycle, carbocycle, CO, CO2, amide, imine; F is single bond, alkyl,alkenyl, alkynyl; G is aryl, heteroaryl, biaryl, bicyclic, tricyclic, aryl, were prepared as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic therapeutic agents. Thus, III was prepared and may be used as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic therapeutic agent (no data).

L1 ANSWER 8 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 143:478161 CA
AB The present invention relates to 14- or 15-membered macrolides substituted at the 3-position I, wherein A is bivalent radical selected from C(O), C(O)NH, NHC(O), N(R7)CH2, CH2N(R7), imine; R1 is ester; R2 is H, hydroxyl protecting group; R3 is H, alkyl, alkenyl optionally substituted by 9 to 10 membered fused bicyclic heteroaryl; R4 is OH, alkenyl-oxy, alkoxy; R5 is OH; R4R5 together with the intervening carbon atoms form a heterocycle; R6 is H, F; R7 is H, alkyl; and pharmaceutically acceptable derivs. thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body. Thus, erythromycin II was prepared and tested in vitro as antibacterial agent. Title compds. were tested in vitro for their antibacterial activity and showed MICs less than 0.125 μg/mL against erythromycin-sensitive and erythromycin-resistant strains of Streptococcus pneumoniae and Streptococcus pyogenes.

L1 ANSWER 9 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 143:460388 CA
AB The present invention relates to 14- or 15-membered macrolides substituted at the 3-position I, wherein A is bivalent radical selected from C(O), C(O)NH, NHC(O), N(R7)CH2, CH2N(R7), imine; R1 is ester; R2 is H, hydroxyl protecting group; R3 is H, alkyl, alkenyl optionally substituted by 9 to 10 membered fused bicyclic heteroaryl; R4 is OH, alkenyl-oxy, alkoxy; R5 is OH; R4R5 together with the intervening carbon atoms form a heterocycle; R6 is H, F; R7 is H, alkyl; and pharmaceutically acceptable derivs. thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body. Thus, erythromycin II was prepared and tested in vitro as antibacterial agent. Title compds. were tested in vitro for their antibacterial activity and showed MICs less than 0.25 μg/mL against erythromycin-sensitive and erythromycin-resistant strains of Streptococcus pneumoniae and Streptococcus pyogenes.

L1 ANSWER 10 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 143:306499 CA
AB The present invention provides macrocyclic azithromycin compds. I and II, wherein T is macrolide; R1 and R3 are independently H, alkyl, alkenyl, alkynyl, acyl ester, amide,thio-acyl, thio-ester, amine; R2 is H, alkoxy; D is single bond, alkyl, alkenyl,alkynyl, acyl, ester, amide, imine, sulfonyl, amine, thio-acyl, thio-amide; E is aromatic heterocycle, carbocycle, CO, CO, amide, imine; F is single bond, alkyl,alkenyl, alkynyl; G is aryl, heteroaryl, biaryl, bicyclic, tricyclic, aryl, were prepared as antibacterial, anti-proliferative, prokinetic, and antiinflammatory agents. Thus, III was prepared and used as antibacterial, anti-proliferative, and antiinflammatory agent.

L1 ANSWER 11 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 142:355522 CA
AB Macrolide 9a,11-3C-bicyclic 9a-azalide erythromycin analogs I, wherein A

is ORp, where Rp is a hydroxy protecting group, R1, where R1 is independently aryl, heteroaryl, OR1, R3, where R3 is H, alkyl, heteroalkyl, alkenyl, , hetero-alkenyl, alkynyl, hetero-alkynyl, OR3sulfonyl, amide, sulfonamide, amine; B is deuterium, OH, R1, R3, ORp, halogen; A and B together with the carbon atom to which they are attached are CO, acyl, ester, oxime, imine; G is H, alkyl, alkenyl, alkynyl,; L is CH(OH)CH3, alkyl, alkenyl, alkynyl; W is H, alkyl, alkenyl, alkynyl; X is H; Y is H, OH, ORp, alkoxy, ester, sulfonyl, sugar residue; Z is H, Me, halogen; R2 is H, Rp, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which exhibit antibacterial properties. The present invention further relates to pharmaceutical compns. comprising the aforementioned compds. for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compds. of the present invention. The invention further includes process by which to make the compds. of the present invention. Thus, I (A and B are taken together with the carbon atom to which they are attached to form C=CH2, L is Et, W = G = Z = R2 = H, X and Y taken together are oxo) was prepared and tested as antibacterial agent.

L1 ANSWER 12 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 142:240672 CA
AB N-Des-methyl-N-substituted-11-deoxy-erythromycins I: wherein R1, R4, and R6 are independently H, Me; R2 is alkyl, alkenyl, alkynyl; R3 and R5 are independently H, OH, were prepared as pro-kinetic agents and can be used to treat disorders of gastric motility. Thus, N-des-methyl-N-isopropyl-1-deoxy-erythromycin B was prepared as pro-kinetic agent and can be used to treat disorders of gastric motility. Compds. of this invention were tested for in vitro activity against three erythromycin sensitive strains of Streptococcus pneumoniae (ATCC 6301, ATCC 700671, and ATCC 49619). N-des-methyl-N-isopropyl-1-deoxy-erythromycin B showed Motilin Agonist activity (EC50 700 nM).

L1 ANSWER 13 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 142:38480 CA
AB 11-12 Bicyclic erythromycin macrolides I, wherein A and B are halogen, NO2, CN, R1, OR1, S(O)nR1, NR1C(O)R2, NR1C(O)NR3R4, NHS(O)nR1, C(O)NR3R4, OC(O)NR3R4 and NR3R4; each R1 and R2 is H , D, acyl, silane, aliphatic, alicyclic, aromatic, heteroarom., heterocyclic; each of R3 and R4 is H , acyl, aliphatic, alicyclic, aromatic, heteroarom., heterocyclic; R3R4 together with the nitrogen atom to which they are attached form heterocyclic or heteroarom. ring; AB, taken together with the carbon atom to which they are attached form alicyclic, aromatic, heterocyclic or heteroarom. ring, CO, C:CR1R2, C:NR1, C:NOR1, C:NO(CH2)mR1, C:NNHR1, C:NNHCOR1, C:NNHCONR3R4, C:NNHS(O)nR1, C:N-N:CR1R2; L is H , aliphatic, alicyclic, aromatic, heteroarom., or heterocyclic; G is H , CN or OR1; one of U or V are independently H, R1, OR1, OC(O)R1, OC(O)NR3R4, S(O)nR1, sugar; UV taken together with the carbon atom to which they are attached, are CO; R5 and R6 is H or Me, and the other is independently halogen, deuterium, or R1; Q is NR3R4; one of X and Y is H, aliphatic, and the other is OH , SH, NH2, or NHR1; or X and Y, taken together with the carbon atom to which they are attached, are C:O, C:C(R1)2, C:NR1, C:NOR1, C:NO(CH2)mR1, C:NNHR1, C:NNHCOR1, C:NNHCONR3R3, C:NNHS(O)nR1, or C:N-N:C(R1)2; R2' is H or a OH protecting ; X1 is H or halogen; m is an integer; and n is 0-2, were prepared as antibacterial agents. The present invention further relates to pharmaceutical compns. comprising the aforementioned compds. for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compds. of the present invention. The compds. of the invention generally demonstrated in vitro an MIC in the range from about 64 μg/mL to about 0.03 μg/mL. The pharmaceutical compns. of this invention can be administered orally to fish by blending said pharmaceutical compns. into fish feed or said pharmaceutical compns.

may be dissolved in water in which infected fish are placed, a method commonly referred to as a medicated bath. Generally, a dosage of 5 - 1000 mg, preferably 20 - 100 mg, per kg of body weight of fish may be administered per day, either at one time or divided into several times.

L1 ANSWER 14 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 142:38478 CA
AB 11-12 Bicyclic erythromycin macrolides I, wherein A and B are halogen, NO2, CN, R1, OR1, S(O)nR1, NR1C(O)R2, NR1C(O)NR3R4, NHS(O)nR1, C(O)NR3R4, OC(O)NR3R4 and NR3R4; each R1 and R2 is H , D, acyl, silane, aliphatic, alicyclic, aromatic, heteroarom., heterocyclic; each of R3 and R4 is H , acyl, aliphatic, alicyclic, aromatic, heteroarom., heterocyclic; R3R4 together with the nitrogen atom to which they are attached form heterocyclic or heteroarom. ring; AB, taken together with the carbon atom to which they are attached form alicyclic, aromatic, heterocyclic or heteroarom. ring, CO, C:CR1R2, C:NR1, C:NOR1, C:NO(CH2)mR1, C:NNHR1, C:NNHCOR1, C:NNHCONR3R4, C:NNHS(O)nR1, C:N-N:CR1R2; L is H , aliphatic, alicyclic, aromatic, heteroarom., or heterocyclic; G is H , CN or OR1; one of U or V are independently H, R1, OR1, OC(O)R1, OC(O)NR3R4, S(O)nR1, sugar; UV taken together with the carbon atom to which they are attached, are CO; R5 and R6 is H or Me, and the other is independently halogen, deuterium, or R1; Q is NR3R4; one of X and Y is H, aliphatic, and the other is OH , SH, NH2, or NHR1; or X and Y, taken together with the carbon atom to which they are attached, are C:O, C:C(R1)2, C:NR1, C:NOR1, C:NO(CH2)mR1, C:NNHR1, C:NNHCOR1, C:NNHCONR3R3, C:NNHS(O)nR1, or C:N-N:C(R1)2; R2' is H or a OH protecting ; X1 is H or halogen; m is an integer; and n is 0-2, were prepared as antibacterial agents (no data). The present invention further relates to pharmaceutical compns. comprising the aforementioned compds. for administration to a subject in need of antibiotic treatment (no data). The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compds. of the present invention (no data).

L1 ANSWER 15 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 142:6762 CA
AB The present invention relates to 14- or 15-membered macrolides substituted at the 3-position I, wherein A is bivalent radical selected from -C(O)-, -C(O)NH-, -NHC(O)-, -N(R7)CH2-, -CH2N(R7)-, imine; R1 is ester; R2 is H, hydroxyl protecting group; R3 is H, alkyl, alkenyl optionally substituted by 9 to 10 membered fused bicyclic heteroaryl; R4 is OH, alkenyl-oxy, alkoxy; R5 is OH; R4R5 together with the intervening carbon atoms form a heterocycle; R6 is H, F; R7 is H, alkyl; and pharmaceutically acceptable derivs. thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body. Thus, azithromycin II was prepared and tested in vitro as antibacterial agent. Title compds. were tested in vitro for their antibacterial activity and showed MICs less than 1 μg/mL against erythromycin-sensitive and erythromycin-resistant strains of Streptococcus pneumoniae and Streptococcus pyogenes.

L1 ANSWER 16 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 142:6758 CA
AB The present invention relates to 14- or 15-membered macrolides substituted at the 3-position I, wherein A is bivalent radical selected from C(O), C(O)NH, NHC(O), N(R7)CH2, CH2N(R7), imine; R1 is ester; R2 is H, hydroxyl protecting group; R3 is H, alkyl, alkenyl optionally substituted by 9 to 10 membered fused bicyclic heteroaryl; R4 is OH, alkenyl-oxy, alkoxy; R5 is OH; R4R5 together with the intervening carbon atoms form a heterocycle; R6 is H, F; R7 is H, alkyl; and pharmaceutically acceptable derivs. thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body. Thus, erythromycin II was prepared and tested in vitro as antibacterial agent. Title compds. were tested in vitro for their

antibacterial activity and showed MICs less than 1 μg/mL against erythromycin-sensitive and erythromycin-resistant strains of Streptococcus pneumoniae and Streptococcus pyogenes.

L1 ANSWER 17 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 142:6757 CA
AB The present invention relates to 14- or 15-membered macrolides substituted at the 3-position I, wherein A is bivalent radical selected from C(O), C(O)NH, NHC(O), N(R7)CH2, CH2N(R7), imine; R1 is ester; R2 is H, hydroxyl protecting group; R3 is H, alkyl, alkenyl optionally substituted by 9 to 10 membered fused bicyclic heteroaryl; R4 is OH, alkenyl-oxy, alkoxy; R5 is OH; R4R5 together with the intervening carbon atoms form a heterocycle; R6 is H, F; R7 is H, alkyl; and pharmaceutically acceptable derivs. thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body. Thus, erythromycin II was prepared and tested in vitro as antibacterial agent. Title compds. were tested in vitro for their antibacterial activity and showed MICs less than 1 μg/mL against erythromycin-sensitive and erythromycin-resistant strains of Streptococcus pneumoniae and Streptococcus pyogenes.

L1 ANSWER 18 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 142:6756 CA
AB The present invention relates to 14- or 15-membered macrolides substituted at the 3-position I, wherein A is bivalent radical selected from C(O), C(O)NH, NHC(O), N(R7)CH2, CH2N(R7), imine; R1 is ester; R2 is H, hydroxyl protecting group; R3 is H, alkyl, alkenyl optionally substituted by 9 to 10 membered fused bicyclic heteroaryl; R4 is OH, alkenyl-oxy, alkoxy; R5 is OH; R4R5 together with the intervening carbon atoms form a heterocycle; R6 is H, F; R7 is H, alkyl; and pharmaceutically acceptable derivs. thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body. For oral and parenteral administration to humans, the daily dosage level of the agent may be in single or divided doses. For systemic administration the daily dose as employed for adult human treatment it will range from 2-100 mg/kg body weight, preferably 5-60 mg/kg body weight, which may be administered in 1 to 4 daily doses, for example, depending on the route of administration and the condition of the patient. When the composition comprises dosage units, each unit will preferably contain 200 mg to 1 g of active ingredient. The duration of treatment will be dictated by the rate of response rather than by arbitrary nos. of days. Thus, title macrolide II was prepared and was tested as antibacterial agent. Title compds. have an MIC < 1 μg/mL against S. aureus Smith ATCC 13709, S. pneumoniae, S. pyogenes 3565 and E. faecalis ATCC 29212; MIC < 2 μg/mL against H. influenzae ATCC 49247 and M. catarrhalis ATCC 23246; and MIC < 1 μg/mL against erythromycin resistant strains of Streptococcus pneumoniae and Streptococcus pyogenes.

L1 ANSWER 19 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 141:411193 CA
AB Antimicrobial macrolide and ketolide I, were prepared wherein R is H, substituted alkyl, alkenyl, amide; R1 is H, substituted alkyl, alkenyl, alkynyl, amide, ester, thioester; R2 is H, halogen, alkyl; R3 and R4 are independently H, halogen, substituted alkyl, with the proviso that when q is 0, then R3 and R4 are not both hydrogen; with the proviso that when R1 is Et, and R3 and R4 are hydrogen, then R5 is not 6-fluoro; and with the proviso that when R1 is -CH=CH, and R3 and R4 are hydrogen, then R5 is not 6-Me; R5 is acyl, OH, halogen, NO2, CN, alkyl, cycloalkyl, alkenyl, alkynyl, ether, amine, heteroaryl, aryl; q is 0-4, as well as pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compns. comprising such compds.; methods of treating prophylaxis bacterial infections by the administration of such compds.; and processes for the preparation of the compds. Thus, macrolide II was prepared

and tested in rats as antibacterial agent. The total daily dose of the compds. of this invention administered to a human or other mammal in single or in divided doses can be in amts., for example, from 0.01 to 50 mg/kg body weight or more usually from 0.1 to 25 mg/kg body weight

L1 ANSWER 20 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 141:406156 CA
AB The invention relates to compns. and methods for reducing oxidative stress in a cell. The invention is comprised of contacting a cell with a sulfhydryl protected glutathione or cysteine prodrug thereby increasing intracellular glutathione or L-cysteine levels resulting in reduced hepatotoxicity.

L1 ANSWER 21 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 141:395758 CA
AB Compds. containing spaced N and/or O, by virtue of their ability to inhibit the protease activity of lethal factor from Bacillus anthracis, are useful in the prevention and treatment of anthrax toxicity. Libraries of these compds. are also useful as substrates for screening methods to identify lethal factor inhibitors. Thus, aminodeoxy pseudo-disaccharide I was prepared for treatment of anthrax infection using inhibitors of lethal factor protease activity.

L1 ANSWER 22 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 141:337861 CA
AB A medical device is adapted for at least partial implantation into a body and includes first and second sections along the length of the device. A first therapeutic agent is associated with the first section and a second therapeutic agent is associated with the second section. The first therapeutic agent can be one or more antiproliferative, such as paclitaxel, a paclitaxel derivative, or a paclitaxel prodrug, anticoagulant, antithrombotic, thrombolytic, fibrinolytic, or combination thereof. The second therapeutic agent can be one or more antimicrobials, such as one or more antibiotics. Each of the first and second therapeutic agents can either be posited on one or more surfaces of the resp. section, or impregnated within the section. The device can include a separator to space the first and second sections. A method of making a medical device and a method of establishing access to a vessel within a body are also provided. For example, silicone tubing segments (approx. 0.8 mm i.d., 1.7 mm O.D., 50 mm length, 120 mg weight) cut from silicone catheter samples (5FR single lumen) were swelled by soaking for approx. 20 h in either Freon or hexane. The samples were then loaded with paclitaxel by soaking for approx. 7 h in one of the following solns. containing 4 mg/mL paclitaxel: 100% ethanol, 50/50% Freon/ethanol, and 50/50% hexane/ethanol. After loading, the tubing segments were allowed to dry for approx. 24 h. The amount of paclitaxel loaded into each segment was determined by extracting the tubing in ethanol for approx. 12 h, and assaying the extract by HPLC. On average the tubing segments yielded approx. 61±19 μg paclitaxel. For comparison, 3.0 mm x 15 mm long VFlexPlus coronary stents, which appeared effective in inhibiting restenosis in clin. trial studies, were loaded with approx. 60 μg paclitaxel.

L1 ANSWER 23 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 141:243769 CA
AB Antibiotic 6-O-substituted bicyclic erythromycin macrolides I were prepared, wherein A is OH, alkoxy, R1; R1 is aryl, heteroaryl, OR1, R2; R2 is H, halogen, alkyl, alkenyl, alkynyl,; OR2, sulfonyl, ester, acyl, amide, sulfonamide, amine; B is H, deuterium, CN, NO2, halogen, OH, R1, R2, alkoxy; A and B together with the carbon atom to which they are attached form CO, C(OR2)2, C(SR2)2, ketal ,thioketal, alkylidene, imine; X and Y are independently H, deuterium, OH, alkoxy, amine, alkyl; X and Y together with the C atom to which they are attached form CO, imine, oxime; L is CH(OH)Me, alkyl, alkenyl, alkynyl; W is H, OH, CN, alkoxy, oxy-amide; Z is H, OH, alkoxy, ester, sulfonyl, sugar residue, or pharmaceutically

acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compns. comprising the aforementioned compds. for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compds. of the present invention. The invention further includes process by which to make the compds. of the present invention. Thus, I wherein A and B taken together with the carbon atom to which they are attached are C=CHS(CH2)2Ph, L is Et, W is OMe, X and Y taken together with the carbon atom to which they are attached are C(O), Z is OH, and R2' is H; was prepared and tested in vitro as antibacterial agent. The compds. of the invention generally demonstrated an MIC in the range from about 64 g/mL to about 0.03 g/mL.

L1 ANSWER 24 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 141:89322 CA
AB 6,11-3C-bicyclic 9a-azalide erythromycin derivs. I were prepared, wherein W is -CH2-C(A)=C(B)-CH2-, -CH2-C(A)-C(B)-CH2-; heterocycle-containing alkylidene, A is OH, alkoxy, aryl, heteroaryl, H, halogen, alkyl, alkynyl, alkenyl, sulfonyl, amide, amine, sulfonamide; B is H, deuterium, halogen, OH, aryl, heteroaryl, CO, ester, thioester, oxime, imine; L is Me, Et, CH(OH)Me, alkyl, alkynyl, alkenyl,; D is substituted amine; X is H; Y is H, OH, alkoxy, ester, amide, sulfonyl; X and Y together are oxo; Z is H, Me, halogen; R2 is H, hydroxy protecting group, which exhibit antibacterial properties. The present invention further relates to pharmaceutical compns. comprising the aforementioned compds. for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compds. of the present invention. Thus, I (W is -CH2CH=CHCH2, D is -N(Q)CH2, Q is CH2C.tplbond.C(3-quinolyl), Z is H, X and Y taken together are oxo, L is Et, R2 is H) was prepared and tested in vitro as antibacterial agent (MIC = 64 μg/mL to 0.03 μg/mL). The total daily dose of the compds. of this invention administered to a human or other animal in single or in divided doses can be in amts., for example, from 0.01 to 50 mg/kg body weight or more usually from 0.1 to 25 mg/kg body weight The compds. of the invention generally demonstrated an MIC in the range from about 64 μg/mL to about 0.03 μg/mL.

L1 ANSWER 25 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 141:54574 CA
AB The present invention relates to prodrugs aminodeoxy oligosaccharides X-(L-Y)n, X-(L-Y-L)n, and X-L-L-X1in which X and X1 are the same or different and are pharmaceutically active moieties; L is a linker group; Y is a pharmacokinetic regulator; of pharmaceutical moieties, more specifically antimicrobial agents, methods for their preparation, pharmaceutical formulations containing them and their use in the treatment of microbial infections. Thus, trisaccharide I was prepared and tested in vitro as antibacterial agent against E. coli and P. aeruginosa (MIC values range from 2 to >64 μM). The antimicrobial or antiinfective agent is an antifungal agent, antiparasitic agent, antimycotic agent or antiviral agent (no data). The viral infection is an influenza A or B infection, parainfluenza, mumps or Newcastle disease.

L1 ANSWER 26 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:304027 CA
AB Macrolide anhydrolide erythromycin analogs I, wherein L is CH(OH)Me, substituted alkyl, alkenyl, alkynyl; R1 and R2 are independently substituted alkyl, alkenyl, alkynyl; X is O, substituted imine, S(O)n, where n is 1-2; and pharmaceutically-acceptable compns. comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically-acceptable carrier are described. Also described are a method for treating bacterial infections by administering to an animal a pharmaceutical composition containing a therapeutically effective amount of

a compound of the invention and processes for the preparation of such compds. Thus, I (L = Et, X = S, R = H, R1 = Me, R2 = 2-[6-(dimethylamino-methyleneamino)purin-9-yl]-Et) was prepared and tested in vitro as antibacterial agent. The compds. of the invention generally demonstrated an MIC in the range from about 64 μg/mL to about 0.03 μg/mL.

L1 ANSWER 27 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:271146 CA
AB Antibiotic 6-O-substituted bicyclic erythromycin macrolides I were prepared, wherein A is OH, alkoxy, R1; R1 is aryl, heteroaryl, OR1, R2; R2 is H, halogen, alkyl, alkenyl, alkynyl,; OR2, sulfonyl, ester, acyl, amide, sulfonamide, amine; B is H, deuterium, CN, NO2, halogen, OH, R1, R2, alkoxy; A and B together with the carbon atom to which they are attached form CO, C(OR2)2, C(SR2)2, ketal ,thioketal, alkylidene, imine; X and Y are independently H, deuterium, OH, alkoxy, amine, alkyl; X and Y together with the C atom to which they are attached form CO, imine, oxime; L is CH(OH)Me, alkyl, alkenyl, alkynyl; W is alkyl, alkenyl, alkynyl, Z is H, OH, alkoxy, ester, sulfonyl, sugar residue, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compns. comprising the aforementioned compds. for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compds. of the present invention. The invention further includes process by which to make the compds. of the present invention. Thus, I wherein A and B taken together with the carbon atom to which they are attached are C=CH2, L is CH2CH3, W is CH2CH=CH2, X and Y taken together with the carbon atom to which they are attached are C(O), R4" is C(O)CH3, and R2' is H; was prepared as antibacterial agent (no data).

L1 ANSWER 28 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:236004 CA
AB 6,11-Bicyclic erythromycin macrolides I, wherein A is OH, OR1, R1 is hydroxy protecting group, aryl, heteroaryl, O-aryl, O-heteroaryl, H, halogen, alkyl, alkenyl, alkynyl, sulfonyl, amide, sulfonamide, amine; B is H, deuterium, halogen, OH, aryl, heteroaryl, OR1; A and B together are O, acetal, thioacetal, acyl, alkene, oxime; X and Y are independently H, deuterium, OR1, amine; X and Y together are CO, imine; L is Me, Et, CH(OH)Me, alkyl, alkenyl, alkynyl; W is amine; Z is H, OH, OR1, alkoxy, ester, O-amide, sulfonyl, heterocycle, or pharmaceutically acceptable salts, esters, or prodrugs thereof which exhibit antibacterial properties. The present invention further relates to pharmaceutical compns. comprising the aforementioned compds. for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compds. of the present invention. The invention further includes process by which to make the compds. of the present invention. Title compds. were tested for in vitro antibacterial activity by a micro-dilution method and demonstrated an MIC in the range from about 64 μg/mL to about 0.03 μg/mL. According to the methods of treatment of the present invention, bacterial infections are treated or prevented in a patient such as a human or other animals by administering to the patient a therapeutically effective amount of a compound of the invention, in such amts. and for such time as is necessary to achieve the desired result (no data). Thus, I (A and B together with the carbon atom to which they are attached = C:CH2, X and Y together with the carbon atom to which they are attached = C:NAc, L = Et, W is NMe2, Z = R = H) was prepared and tested as antibacterial agent.

L1 ANSWER 29 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:217956 CA
AB Motilide erythromycin compds. I, wherein R1 is C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, aryl, or hetero-cyclo; R2 is H, C1-C5 alkyl,

C2-C5 alkenyl, C2-C5 alkynyl, aryl, or hetero-cyclo; R3 is H or OH; and R4 is H or OH, or R3 and R4 taken together form O-(C=O)-O; with the proviso that when (a) R1 is Et and (b) R2 is OH or R3 and R4 taken together form O-C(O)-O, then R2 is not H or Me, and methods for their preparation and use in the treatment of diseases or conditions characterized by impaired gastric motility. Thus, I (R1 = Et, R2 = iPr, R3 = R4 = OH) was prepared and tested as antibacterial agent against Streptococcus pneumoniae ATCC 6301 and medicament for treating a disorder of gastric disorder in a patient. Illustrative examples of disorders that may be treated with the inventive compds. include but are not limited to gastro-paresis, gastro-esophageal reflux disease, anorexia, gall bladder stasis, postoperative paralytic ileus, scleroderma, intestinal pseudo-obstruction, gastritis, emesis, and chronic constipation (colonic inertia).

L1 ANSWER 30 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:217887 CA
AB In nature, the attachment of sugars to small mols. is often used to mediate targeting, mechanism of action and/or pharmacol. As an alternative to pathway engineering or total synthesis, we report a useful method, in vitro glycorandomization (IVG), to diversify the glycosylation patterns of complex natural products. We have used flexible glycosyltransferases on nucleotide diphospho-sugar (NDP-sugar) libraries to generate glyco-randomized natural products and then applied chemoselective ligation to produce mono-glycosylated vancomycins that rival vancomycin.

L1 ANSWER 31 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:164138 CA
AB Antibacterial erythromycin derivs. I, wherein R1 is H, Ac, Bz, TMS, triethylsilyl; R2 is -CH=CH-, -C.tplbond.C-; R3 is heterocycle, tetra-azolyl, furanyl, imidazolyl, iso-thiazolyl, isoxazolyl, naphthyl, 1,2,3-oxadiazolyl, oxazolyl, Ph, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, 1,3,4-thiadiazolyl, thiazolyl, pyridyl (pyridinyl), thienyl (thiophenyl), 1,3,5-triazinyl, 1,2,3-triazolyl; X is H, F, heterocycle; with improved pharmacokinetic profiles and salts, prodrugs, and salts of prodrugs thereof, processes for making the compds. and intermediates used in the processes, compns. containing the compds., and methods for prophylaxis and treatment of bacterial infections using the compds. are disclosed. Thus, (3aS,4R,7R,9R,10R,11S,13R,15R,15aR)-10-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4-ethyl-7-fluoro-3a,7,9,11,13,15-hexamethyl-11-(((2E)-3-(5-(2-methyl-2H-tetrazol-5-yl)thien-2-yl)prop-2-enyl)oxy)octahydro-2H-oxacyclotetradecino[4,3-d][1,3]oxazole-2,6,8,14(1H,7H,9H)-tetrone was prepared and tested as antibacterial agent. The daily therapeutically effective amount of the compds. administered to a patient in single or divided doses range from about 0.1 to about 200 mg/kg body weight, preferably from about 0.25 to about 100 mg/kg body weight Compds. of this invention displayed antibacterial activity superior to the control, which control demonstrated no antibacterial activity. The pharmacokinetic profiles were evaluated using cassette dosing protocols in dog at a dose of 1 mg/kg.

L1 ANSWER 32 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:164136 CA
AB Antibacterial tricyclic macrolide erythromycin derivs. I, wherein R1 is H, R11, CO2R11, amide, alkyl; R2 is H, R12; R12 is hydroxy protecting group; one of R3 or R4 is H, the other is OH, OR12; OR11, ester, OCONH2, alkoxy; R3and R4 together are O, CH2O; R5 is H, R11, ester,amide; R6 and R10 are independently H, R13; R7 is O, =NOH, oxime one of R8 and R9 is H, and the other is OH, alkoxy; R8 and R9 together are O; R11-R13 are independently alkyl, (CH2)alkenyl, (CH2)alkynyl, cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl; and salts, prodrugs, and salts of prodrugs thereof, processes for making the compds. and intermediates used in the processes, compns. containing the compds., and methods for prophylaxis or treatment of bacterial infections using the compds. are disclosed. Thus,

(2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-12-fluoro-8-methoxy-3,4a,6,8,10,12,15a-hepta-methyl-2,5,11,13-tetraoxohexadecahydro-2H-1,14-dioxa-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoside was prepared and tested in vitro as antibacterial agent. The ability of the compds. to inhibit bacterial growth in vitro was superior to the control and in the range of about 0.5 μg/mL to greater than about 128 μg/mL.

L1 ANSWER 33 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:146397 CA
AB Novel 6,11-4-carbon bridged erythromycin ketolides I, wherein W is substituted alkylidene, X and Y are independently H, deuterium, OH, alkoxy, amine; XY are together CO, imine, oxime, amide; L is hydroxy-alkyl, alkyl, alkenyl, alkynyl; Z is H, Me, halogen; Rx is hydroxy protecting group; K is H, alkoxy, ester, carbamate, sulfoxide, sugar residue; pharmaceutically-acceptable compns. comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically-acceptable carrier are described. Also described are methods for treating bacterial infections by administering to an animal a pharmaceutical composition containing a therapeutically effective amount of a compound of the invention and processes for the preparation of such compds. Thus, I (W is -CH2CH=CHCH2-, X and Y taken together with the carbon atom they are attached to form C=N-OH, L is Et, Rx = H; K is sugar residue Q) was prepared and tested in vitro as antibacterial agent. The compds. of the invention generally demonstrated an MIC in the range from about 64 μg/mL to about 0.03 μg/mL.

L1 ANSWER 34 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:146396 CA
AB Novel 6,11-4-carbon bridged ketolides I, wherein W is substituted alkylidene, X and Y are independently H, deuterium, OH, alkoxy, amine; XY are together CO, imine, oxime, amide; L is hydroxy-alkyl, alkyl, alkenyl, alkynyl; Z is H, Me, halogen; Rx is hydroxy protecting group, pharmaceutically-acceptable compns. comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically-acceptable carrier are described. Also described are a method for treating bacterial infections by administering to an animal a pharmaceutical composition containing a therapeutically effective amount of a compound of the invention and processes for the preparation of such compds. Thus, I (W is -CH2CH=CHCH2-, X and Y taken together with the carbon atom they are attached to form C=NC(O)CH3, L is Et, Z = Rx = H) was prepared and tested in vitro as antibacterial agent. The compds. of the invention generally demonstrated antibacterial activity in vitro with an MIC in the range from about 64 μg/mL to about 0.03 μg/mL.

L1 ANSWER 35 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:111633 CA
AB Antibacterial compds. having formula I and formula II, wherein R1 is H, OH, ether, O-amide, O-ester; R2 is H, hydroxyl protecting group, R3 and R4 are independently H, OH, ether, O-ester, NH2, amine, O-amide, O-ester; R3R4 are together O, oxime; R5 and R6 are independently H, OH, ether, O-ester, NH2, amine, O-amide,; R5R6 are together O; R7 and R8 are independently OH, ether, ester, O-ester, O-amide, ether; R7R8 are together OX1 is H, F, Cl, Br; and salts, prodrugs, and salts of prodrugs thereof, processes for making the compds. and intermediates employed in the processes, compns. containing the compds., and methods for prophylaxis or treatment of bacterial infections in a fish or a mammal using the compds. are disclosed. Thus, I [R1 = OH, R2 = R3 = R6 = R7 = H, R4 = NH2, R6 = (2-aminoethyl)NH(O)CO] was prepared and tested in vitro as antibacterial agent.

L1 ANSWER 36 OF 55 CA COPYRIGHT 2007 ACS on STN

AN 140:94231 CA
AB Antibacterial compds. having formula I and formula II, wherein one of A and B is CH2 and the other is NR8; R1 is H, alkyl; R1R8 is CH2, CO; R2 is H, hydroxy protecting group; R3 is H and R4 is OH, alkoxy, O-ester, OCONH2, O-amide, ether; R3R4 is O; R5 is H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocycle, NH2, substituted amine, ester, amide; one of R6 and R7 is H and the other is OH, ether, ester, O-ester, O-amide; R6R7 together are O, CH2O; R8 is H, ester, amide, X1 is H, F; and salts, prodrugs, and salts of prodrugs thereof, processes for making the compds. and intermediates used in the processes, compns. containing the compds., and methods for prophylaxis or treatment of bacterial infections using the compds. are disclosed. Thus, (2R,3S,5S,8R,10S,11R,12S,13S,14R)-2-ethyl-3,10-dihydroxy-3,5,8,10,12,14-hexamethyl-15-oxo-11-((3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-13-yl-2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranoside was prepared and. Compds. of this invention displayed in vitro antibacterial activity in the range of about 0.03 μg/mL to greater than about 128 μg/mL . It is meant to be understood that certain metabolites of compds. of this invention, which metabolites are produced by in vitro or in vivo metabolic processes, would also be useful as antibacterials.

L1 ANSWER 37 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:77362 CA
AB Macrolide erythromycin I, in which R1 is H, R; R is a OH protecting moiety; R3 is CH2R4, CH2CH2R5, CH2CH2R6; R4 is alkyl; R5 and R6 are independently alkenyl interrupted with one or two moieties independently selected from the group consisting of O, =N, NH, N(alkyl), S, S(O), S(O)2; X1 is hydrogen or fluoride, were prepared and which are useful as antibacterials for penicillin-resistant Streptococcus pneumoniae, prodrugs, and salts of prodrugs thereof, processes for making the compds. and intermediates used in the processes, compns. containing the compds., and methods for prophylaxis or treatment of bacterial infections. Thus, (3R,5R,6R,7S,9R,10E,11S,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-12,13-dihydroxy-7-methoxy-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,4,10-trione was prepared and tested as antibacterial agent. Compds. of this invention displayed antibacterial activity against penicillin-resistant Streptococcus pneumoniae superior to the control, which control demonstrated no antibacterial activity (no data).

L1 ANSWER 38 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:77361 CA
AB The present invention discloses preparation of erythromycin macrolide analogs, such as I [A, B, D, E = H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocycle, CN, OH, SH, CO2H, ester, amide, etc.; AD, AE, BD = one- to five-membered alkylene, two- to five-membered hetero-alkylene; AB, DE = one- to seven-membered alkylene, two- to seven-membered hetero-alkylene; L = alkylene, alkynylene, amine, imine, etc.; Z = (E)-CH=CH, (Z)-CH=CH, C.tplbond.C; R = H, protecting group; W = H, aryl, heteroaryl, heterocycle; X = H, F; Y = arylene, hetero-arylene], and salts, prodrugs, and salts of prodrugs thereof, for treating bacterial infections. Thus, title compds. were prepared and tested for their antibacterial activity against Staphylococcus aureus, Streptococcus pyogenes and Streptococcus pneumoniae. Thus, (2R,4R,5R,6R,8R,11R,12S,19R,20R)-11-ethyl-2,4,6,8,12,19-hexamethyl-7,9,14-trioxo-4-(3-(5-((phenylamino)methyl)thien-2-yl)prop-2-ynyl)-10,13-dioxa-15,18-diaza-tricyclo[10.6.2.015,20]icos-1(18)-en-5-yl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoside, was prepared and tested in vitro as antibacterial agent.

L1 ANSWER 39 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:59899 CA
AB There are described 11-C-substituted derivs. of erythromycin I, wherein A

is substituted alkyl, alkenyl, alkynyl, acyl, ester, amide; B, C, D may be present singly or in combination and are independently bond, H, halogen, alkyl, aryl, heterocyclic, ether, O, oxime, hydrazine, S, amine; R is H, hydroxy protecting group; R1 is H, alkyl, alkenyl, alkynyl, acyl, ester, amide; W is H, halogen, alkyl, alkenyl, alkynyl, and pharmaceutically acceptable compns. comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier. Also described is a method for treating bacterial infections by administering to an animal a pharmaceutical composition containing a therapeutically-effective amount of a compound of the invention, and processes for the preparation of such compds. Thus, I (A = CHO, B and D together are O, C = R = R1 = W = H) was prepared and tested in vitro as antibacterial agent. Compds. were tested for in vitro antibacterial activity by a micro-dilution method. The compds. of the invention generally demonstrated an MIC in the range from about 64 μg/mL to about 0.03 μg/mL.

L1 ANSWER 40 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 140:16930 CA
AB 3-Descladinosyl-6-O-carbamoyl and 6-O-carbonoyl macrolide of the formula I, wherein R1 is H, alkyl, alkenyl, alkynyl, wherein the substituents are independently halogen, alkyl, alkenyl, alkynyl, cycloalkyl, oxo, aryl, heteroaryl, heterocyclo, CN, nitro, ester, carboxylate, ether, thioether, sulfoxide, sulfonyl, acyl, amide; R3 is H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl; R4 is H or a hydroxy protecting group; R5 is H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclo, arylalkyl, arylalkenyl, arylalkynyl, heterocycloalkyl, heterocycloalkenyl, and heterocycloalkynyl, cycloalkyl, cycloalkenyl, alkoxyalkyl; L is absent or C(O); W is NH or O; X and X', together with the carbon atom to which they are attached, form C=O, C=NRc, or C=NORc, wherein Rc is independently selected from H, alkyl, alkenyl and alkynyl; and Z is selected from C(O), C(O)-O, amide, and SO2; R6 is aryl, heteroaryl, heterocyclyl, cycloalkyl, alkyl, alkenyl,alkynyl, wherein the substituents are selected from halogen, alkyl, alkenyl, alkynyl, cycloalkyl, oxo, alkoxyimino, aryl, heteroaryl, heterocyclo, CN, nitro, ester, carboxylate, ether, thioether, sulfoxide, sulfonyl, acyl, amide; were prepared as antibacterial agents, wherein the condition is selected from community-acquired pneumonia, upper and lower respiratory tract infections, skin and soft tissue infections, meningitis, hospital-acquired lung infections, and bone and joint infections. Thus, macrolide II was prepared and tested in vitro as antibacterial agent (MIC range from 0.03 to > 16 μg/mL). The bacterium is selected from Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Enterococcus spp., Moraxella catarrhalis and H. influenzae.

L1 ANSWER 41 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 139:396138 CA
AB 6,11-Bicyclic erythromycin macrolides I, wherein A is OH, OR1, R1 is hydroxy protecting group, aryl, heteroaryl, O-aryl, O-heteroaryl, H, halogen, alkyl, alkenyl, alkynyl, sulfonyl, amide, sulfonamide, amine; B is H, deuterium, halogen, OH, aryl, heteroaryl, OR1; A and B together are O, acetal, thioacetal, acyl, alkene, oxime; X and Y are independently H, deuterium, OR1, amine; X and Y together are CO, imine; L is Me, Et, CH(OH)Me, alkyl, alkenyl, alkynyl; W is amine; Z is H, OH, OR1, alkoxy, ester, O-amide, sulfonyl, heterocycle, or pharmaceutically acceptable salts, esters, or prodrugs thereof which exhibit antibacterial properties. The present invention further relates to pharmaceutical compns. comprising the aforementioned compds. for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compds. of the present invention. The invention further includes process by which to make the compds. of the present invention. Title compds. were tested for in vitro antibacterial activity by a micro-dilution method and demonstrated an MIC in the range from about 64 μg/mL to about 0.03 μg/mL. According to the methods of treatment of

the present invention, bacterial infections are treated or prevented in a patient such as a human or other animals by administering to the patient a therapeutically effective amount of a compound of the invention, in such amts. and for such time as is necessary to achieve the desired result (no data). Thus, I (A and B together with the carbon atom to which they are attached = C:CH2, X and Y together with the carbon atom to which they are attached = C:NAc, L = Et, W is NMe2, Z = R = H) was prepared and tested as antibacterial agent.

L1 ANSWER 42 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 139:381701 CA
AB Antibacterial erythromycin derivs. I, wherein R1 is H, Ac, Bz, TMS, triethylsilyl; R2 is -CH=CH-, -C.tplbond.C-; R3 is heterocycle, tetra-azolyl, furanyl, imidazolyl, iso-thiazolyl, isoxazolyl, naphthyl, 1,2,3-oxadiazolyl, oxazolyl, Ph, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, 1,3,4-thiadiazolyl, thiazolyl, pyridyl (pyridinyl), thienyl (thiophenyl), 1,3,5-triazinyl, 1,2,3-triazolyl; X is H, F, heterocycle; with improved pharmacokinetic profiles and salts, prodrugs, and salts of prodrugs thereof, processes for making the compds. and intermediates used in the processes, compns. containing the compds., and methods for prophylaxis and treatment of bacterial infections using the compds. are disclosed. Thus, (3aS,4R,7R,9R,10R,11S,13R,15R,15aR)-10-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4-ethyl-7-fluoro-3a,7,9,11,13,15-hexamethyl-11-(((2E)-3-(5-(2-methyl-2H-tetrazol-5-yl)thien-2-yl)prop-2-enyl)oxy)octahydro-2H-oxacyclotetradecino[4,3-d][1,3]oxazole-2,6,8,14(1H,7H,9H)-tetrone was prepared and tested as antibacterial agent. The daily therapeutically effective amount of the compds. administered to a patient in single or divided doses range from about 0.1 to about 200 mg/kg body weight, preferably from about 0.25 to about 100 mg/kg body weight Compds. of this invention displayed antibacterial activity superior to the control, which control demonstrated no antibacterial activity. The pharmacokinetic profiles were evaluated using cassette dosing protocols in dog at a dose of 1 mg/kg.

L1 ANSWER 43 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 139:365175 CA
AB Antibacterial tricyclic macrolide erythromycin derivs. I, wherein R1 is H, R11, CO2R11, amide, alkyl; R2 is H, R12; R12 is hydroxy protecting group; one of R3 or R4 is H, the other is OH, OR12; OR11, ester, OCONH2, alkoxy; R3and R4 together are O, CH2O; R5 is H, R11, ester,amide; R6 and R10 are independently H, R13; R7 is O, =NOH, oxime one of R8 and R9 is H, and the other is OH, alkoxy; R8 and R9 together are O; R11-R13 are independently alkyl, (CH2)alkenyl, (CH2)alkynyl, cycloalkyl, halo, aryl, heteroaryl, and heterocyclyl; and salts, prodrugs, and salts of prodrugs thereof, processes for making the compds. and intermediates used in the processes, compns. containing the compds., and methods for prophylaxis or treatment of bacterial infections using the compds. are disclosed. Thus, (2aR,4aS,6R,8S,9R,10R,12R,15R,15aS,15bS)-15-ethyl-12-fluoro-8-methoxy-3,4a,6,8,10,12,15a-hepta-methyl-2,5,11,13-tetraoxohexadecahydro-2H-1,14-dioxa-3-azacyclotetradeca(1,2,3-cd)pentalen-9-yl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranoside was prepared and tested in vitro as antibacterial agent. The ability of the compds. to inhibit bacterial growth in vitro was superior to the control and in the range of about 0.5 μg/mL to greater than about 128 μg/mL.

L1 ANSWER 44 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 139:365174 CA
AB 6,11-3C-bicyclic 9a-azalide erythromycin derivs. I were prepared, wherein A is OH, alkoxy, aryl, heteroaryl, H, halogen, alkyl, alkynyl, alkenyl, sulfonyl, amide, amine, sulfonamide; B is H, deuterium, halogen, OH, aryl, heteroaryl, CO, ester, thioester, oxime, imine; L is Me, Et, CH(OH)Me, alkyl, alkynyl, alkenyl,; D is substituted amine; X is H; Y is H, OH, alkoxy, ester, amide, sulfonyl; X and Y together are oxo; Z is H, Me, halogen; R2 is H, hydroxy protecting group, which exhibit antibacterial

properties. The present invention further relates to pharmaceutical compns. comprising the aforementioned compds. for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compds. of the present invention. Thus, I (AB = :CH2, D = NHMe, X = Z = H, Y = OH, L = Et, R2 = Ac) was prepared and tested in vitro as antibacterial agent (MIC = 0.03 μg/mL). The total daily dose of the compds. of this invention administered to a human or other animal in single or in divided doses can be in amts., for example, from 0.01 to 50 mg/kg body weight or more usually from 0.1 to 25 mg/kg body weight The compds. of the invention generally demonstrated an MIC in the range from about 64 μg/mL to about 0.03 μg/mL.

L1 ANSWER 45 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 139:365172 CA
AB Antibacterial erythromycin 9-oxime macrolides I, wherein X1 is H, F; R1 is alkyl, -(CH2)alkenyl, -(CH2)alkynyl, R2 is hydrogen, alkyl, -(CH2)alkenyl, -(CH2)alkynyl, R3 is hydrogen or R, in which R is a hydroxyl protecting moiety; one of R4 and R5 is hydrogen and the other is -OH; or R4 and R5 together are =O; and salts, prodrugs, and salts of prodrugs thereof, processes for making the compds. and intermediates used in the processes, compns. containing the compds., and methods for prophylaxis or treatment of bacterial infections using the compds. are disclosed. Thus, I [R1 = 3-(quinolin-3-yl)prop-2-ynyl; R2 = methyl; R3 = hydrogen; R4 and R5 taken together are = O; and X = fluoro] was prepared and tested in vitro as antibacterial agent. Compds. of this invention displayed in vitro antibacterial activity in the range of about 0.008 μg/mL to greater than about 128 μg/mL.

L1 ANSWER 46 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 139:365171 CA
AB Antibacterial compds. having formula I and formula II, wherein R1 is H, OH, ether, O-amide, O-ester; R2 is H, hydroxyl protecting group, R3 and R4 are independently H, OH, ether, O-ester, NH2, amine, O-amide, O-ester; R3R4 are together O, oxime; R5 and R6 are independently H, OH, ether, O-ester, NH2, amine, O-amide,; R5R6 are together O; R7 and R8 are independently OH, ether, ester, O-ester, O-amide, ether; R7R8 are together OX1 is H, F, Cl, Br; and salts, prodrugs, and salts of prodrugs thereof, processes for making the compds. and intermediates employed in the processes, compns. containing the compds., and methods for prophylaxis or treatment of bacterial infections in a fish or a mammal using the compds. are disclosed. Thus, I [R1 = OH, R2 = R3 = R6 = R7 = H, R4 = NH2, R6 = (2-aminoethyl)NH(O)CO] was prepared and tested in vitro as antibacterial agent.

L1 ANSWER 47 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 139:365170 CA
AB Antibacterial compds. having formula I and formula II, wherein one of A and B is CH2 and the other is NR8; R1 is H, alkyl; R1R8 is CH2, CO; R2 is H, hydroxy protecting group; R3 is H and R4 is OH, alkoxy, O-ester, OCONH2, O-amide, ether; R3R4 is O; R5 is H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocycle, NH2, substituted amine, ester, amide; one of R6 and R7 is H and the other is OH, ether, ester, O-ester, O-amide; R6R7 together are O, CH2O; R8 is H, ester, amide, X1 is H, F; and salts, prodrugs, and salts of prodrugs thereof, processes for making the compds. and intermediates used in the processes, compns. containing the compds., and methods for prophylaxis or treatment of bacterial infections using the compds. are disclosed. Thus, (2R,3S,5S,8R,10S,11R,12S,13S,14R)-2-ethyl-3,10-dihydroxy-3,5,8,10,12,14-hexamethyl-15-oxo-11-((3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-13-yl-2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranoside was prepared and. Compds. of this invention displayed in vitro antibacterial activity in the range of about 0.03 μg/mL to greater than about 128 μg/mL . It is meant to be understood that

certain metabolites of compds. of this invention, which metabolites are produced by in vitro or in vivo metabolic processes, would also be useful as antibacterials.

L1 ANSWER 48 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 139:350908 CA
AB Antibacterial erythromycin derivs. I, wherein R1 is H, Ac, Bz, TMS, triethylsilyl; R2 is -CH=CH-, -C.tplbond.C-; R3 is heterocycle, tetra-azolyl, furanyl, imidazolyl, iso-thiazolyl, isoxazolyl, naphthyl, 1,2,3-oxadiazolyl, oxazolyl, Ph, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, 1,3,4-thiadiazolyl, thiazolyl, pyridyl (pyridinyl), thienyl (thiophenyl), 1,3,5-triazinyl, 1,2,3-triazolyl; X is H, F, heterocycle; with improved pharmacokinetic profiles and salts, prodrugs, and salts of prodrugs thereof, processes for making the compds. and intermediates used in the processes, compns. containing the compds., and methods for prophylaxis and treatment of bacterial infections using the compds. are disclosed. Thus, (3aS,4R,7R,9R,10R,11S,13R,15R,15aR)-10-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4-ethyl-7-fluoro-3a,7,9,11,13,15-hexamethyl-11-(((2E)-3-(5-(2-methyl-2H-tetrazol-5-yl)thien-2-yl)prop-2-enyl)oxy)octahydro-2H-oxacyclotetradecino[4,3-d][1,3]oxazole-2,6,8,14(1H,7H,9H)-tetrone was prepared and tested as antibacterial agent. The daily therapeutically effective amount of the compds. administered to a patient in single or divided doses range from about 0.1 to about 200 mg/kg body weight, preferably from about 0.25 to about 100 mg/kg body weight Compds. of this invention displayed antibacterial activity superior to the control, which control demonstrated no antibacterial activity. The pharmacokinetic profiles were evaluated using cassette dosing protocols in dog at a dose of 1 mg/kg.

L1 ANSWER 49 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 139:338165 CA
AB There are described novel 5-O-mycaminosyltylonide (OMT) analogs I, wherein A and B are independently CHO, CN, CH:N-OR5, CH:CHNR5R6; R is H, hydroxy protecting group; R1 and R2 are independently H, OH, protected OH, alkyloxycarbonyl, OR5, halogen, NR5R6; R1R2 together are O; R3 is H, hydroxy protecting group, acyl, alkyl, alkenyl, alkynyl; R4 is M-Y, wherein M is CO, amide, alkyl-NR5, alkenyl-NR5, alkynyl-NR5; Y is H, alkyl, alkenyl, alkynyl, aryl, heterocycle; R5 and R6 are independently H, alkyl, alkenyl, alkynyl; R5R6 are O, NH, S, SO, SO2, N-alkyl, N-aryl, heteroaryl; possessing increased antibacterial activity toward Gram pos. and Gram neg. bacteria as well as macrolide resistant Gram positives and pharmaceutically acceptable compns. comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier. Also described are a method for treating bacterial infections by administering to a patient a pharmaceutical composition containing a therapeutically-effective amount of a compound of the invention, and processes for the preparation of such compds. Thus, I (A = CHO, B = CH2-NH2Me2, R1 and R2 taken together are = O, R = R3 = R4 = H) was prepared and tested as antibacterial agent. Also described are a method for treating bacterial infections by administering to an animal a pharmaceutical composition containing a therapeutically-effective amount of a compound of the invention, and processes for the preparation of such compds. Minimal Inhibitory Concentration (MIC) was determined in 96 well μL plates utilizing the appropriate Mueller Hilnton Broth medium (CAMHB) for the observed bacterial isolates. In general, treatment regimens according to the present invention comprise administration to a patient in need of such treatment from about 10 mg to about 1000 mg of the compound(s) of the compds. of the present invention per day in single or multiple doses. The compds. of the invention generally demonstrated an MIC in the range from about 64 μg/mL to about 0.03 μg/mL.

L1 ANSWER 50 OF 55 CA COPYRIGHT 2007 ACS on STN

AN 139:338164 CA
AB There are described novel 5-O-mycaminosyltylonide (OMT) analogs I, wherein A is CHO, CN, CH:N-OR6, CH:CHNR6R7; R is H, hydroxy protecting group; R1 and R2 are independently H, OH, protected OH, alkyloxycarbonyl, OR6, halogen, NR6R7; R1R2 together are O; R3 is H, hydroxy protecting group, acyl, alkyl, alkenyl, alkynyl; R4 and R5 are independently M-Y, wherein M is CO, amide, alkyl-NR6, alkenyl-NR6, alkynyl-NR6; Y is H, alkyl, alkenyl, alkynyl, aryl, heterocycle; R6 and R7 are independently H, alkyl, alkenyl, alkynyl; R6R7 are O, NH, S, SO, SO2, N-alkyl, N-aryl, heteroaryl; possessing increased antibacterial activity toward Gram pos. and Gram neg. bacteria as well as macrolide resistant Gram positives and pharmaceutically acceptable compns. comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier. Also described are a method for treating bacterial infections by administering to a patient a pharmaceutical composition containing a therapeutically-effective amount of a compound of the invention, and processes for the preparation of such compds. Thus, I (A = -CHO, R1 and R2 taken together are = O, R = R3 = R4 = H, R5 = 4-quinoline-carboxyl) was prepared and tested as antibacterial agent. Compds. were tested for in vitro antibacterial activity by a micro-dilution method. Minimal Inhibitory Concentration (MIC) was determined in 96 well μL plates utilizing the appropriate Mueller Hilnton Broth medium (CAMHB) for the observed bacterial isolates. The compds. of the invention generally demonstrated an MIC in the range from about 64 μg/mL to about 0.03 μg/mL. In general, treatment regimens according to the present invention comprise administration to a patient in need of such treatment from about 10 mg to about 1000 mg of the compound(s) of the compds. of the present invention per day in single or multiple doses.

L1 ANSWER 51 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 137:210903 CA
AB The invention discloses the use of 5-substituted nucleosides and/or prodrugs thereof together with at least one active substance in order to produce a medicament or combination preparation used in the resistance-free treatment of infectious diseases caused by bacteria or protozoa.

L1 ANSWER 52 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 136:156403 CA
AB This invention provides methods and systems to identify enzymes that act as enzyme-catalyzed therapeutic activators and the enzymes identified by these methods. Also provided by this invention are compds. activated by the enzymes as well as compns. containing these compds.

L1 ANSWER 53 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 135:195449 CA
AB Coumarin derivs., such as I [X = CH, CH2, NH, O, S; Y = H, O; R1 = H, alkyl, NH2, aminoalkyl, OR5; R2-R4 = H, OH, alkoxy, OR5; R3R4 = 5 or 6 membered heterocyclic ring; R5 = C5-20 alkyl, C5-20 alkenyl, C5-20 alkylene(C3-6 cycloalkyl), C5-20 alkenylene(C3-6cycloalkyl), C5-20 alkylene(heterocycle) and C5-20 alkenylene(heterocycle), where heterocycle represents a 3 to 5 membered heterocyclic ring containing at least one oxygen heteroatom and where said cycloalkyl or heterocycle can be substituted with one or more C1-4 alkyl; dashed line = single bond or double bond], a pharmaceutically acceptable salt or prodrug thereof, were either isolated from grapefruit oil or prepared as P-glycoprotein inhibiting compds. for lowering the resistance of target cells to selected therapeutic agents. The coumarin derivs. were tested as P-glycoprotein inhibitors for enhancing the antimicrobial and antitumor activities of other antimicrobial and cytotoxic agents. Thus, coumarin derivative II isolated from grapefruit oil combined with ethidium bromide showed susceptibility (MIC) of methicillin sensitive staphylococcus aureus (MSSA) at a concentration of 30μg/mL. The P-glycoprotein inhibitory activity for II

(20μg/mL) in MCF-7/ADR cells was compared with verapamil (40μg/mL).

L1 ANSWER 54 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 133:115890 CA
AB The invention relates to a process for the selection from a gene library of a gene encoding an enzyme that is capable of catalyzing the conversion of a prodrug to its active drug form. The method comprises contacting a library of lysogenic bacteria with a prodrug that causes activation of bacterial RecA when converted to its active drug form. Activation of RecA causes lysis of the bacteria, so allowing separation of bacteriophage particles released into the medium, and their subsequent genotypic anal. to isolate nucleic acid mols. in the library that encode a desired prodrug-activating enzyme.

L1 ANSWER 55 OF 55 CA COPYRIGHT 2007 ACS on STN
AN 125:104145 CA
AB A new model for the evaluation of antifungal compds. against oropharyngeal and gastrointestinal mucosal colonization by Candida albicans was developed. To simulate the immune deficiency observed in AIDS patients, mice were depleted of CD4+ T lymphocytes by the injection of either GK1.5 hybridoma cells or purified anti-CD4+ monoclonal antibody derived from GK1.5 hybridoma cells in tissue culture. Fluorescence-activated cell sorter anal. of splenic lymphocytes confirmed the elimination of the CD4+ T-cell population. Gentamicin, a broad-spectrum, non-absorbable aminoglycoside antibiotic, was given via the drinking water to reduce the normal gastrointestinal microflora, allowing less competition for colonization of the gastrointestinal tract by the C. albicans isolates. Mice were challenged by gavage and swabbing their oral mucosa with a pure culture of C. albicans. Gentamicin was withdrawn 3 days post-challenge, and antifungal compds. were administered via the drinking water ad libitum at concns. ranging from 25-400 μg/mL. L-693989, a water-soluble phosphorylated cyclic lipopeptide prodrug of pneumocandin Bo, and L-733560, a semisynthetic derivative of pneumocandin Bo, are inhibitors of 1,3-β-D-glucan synthesis that exhibit potent in vivo anti-Candida spp. and anti-Pneumocystis carinii activities. The efficacies of L-693989, L-733560, fluconazole, ketoconazole, and nystatin were evaluated in this new oropharyngeal and gastrointestinal model of mucosal colonization. L-693989, L-733560, fluconazole, and ketoconazole showed superior efficacies in reducing the nos. of C. albicans CFU per g of feces and the nos. of oral CFU relative to those in sham-treated controls in this model, while nystatin was moderately effective in reducing oral and fecal colonization by C. albicans in this model.